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1. INTRODUCTION 
Dosage forms design is associated with a great challenge to match the pharmacological/therapeutical 
expectations of the clinical practice with the attributes of the active pharmaceutical ingredients (API) 
and the biopharmaceutical environment of the targeted administration route. Poor aqueous solubility 
is one of the major challenges concerning the APIs in this complex development process within the 
task of pharmaceutical technology. Therefore, special interest can be seen on these Class II and IV 
drugs of the BCS (Lipinski, 2002, 1997). 
Solubility enhancement and using alternative routes of administration are the main leading strategies 
to make these drugs available for the patients in several cases (Kansara et al., 2015; Peterson et al., 
2019). The combination of the mentioned strategies is advised for drugs that have both weaknesses, 
namely (1) suffer from poor water solubility and (2) are extensively metabolized by the first-pass 
metabolism (Bartos et al., 2018). 
As a potential solution for the first challenge is nanosizing (nanotechnology) as the nanoscale-sized 
particles of an API exhibit higher solubility and dissolution rate compared to their large counterparts. 
It can be seen through the evaluating the new delivery pathways, that intranasal delivery has recently 
received a high interest as an alternative route of administration, as a promising route of administration 
for local, systemic, brain, and vaccine therapy. Moreover, combining these two strategies, one can lead 
to an innovative product, namely an intranasal nanosystem based formulation making the API 
available for both systemic use and brain targeting (Alshweiat et al., 2019a). 
Loratadine (LOR) is the most frequently prescribed antihistamine drug for the treatment of various 
allergic conditions. Moreover, LOR has been introduced as a safe and effective emergency therapy for 
the management of bone pain in particular cases (Moore and Haroz, 2017). This API exhibits poor and 
variable bioavailability. Therefore, the delivery of LOR in a new dosage form based on a nanosized 
system could be advantageous to improve the bioavailability and introduce a new preparation of LOR 
of high patient acceptance. 
From regulatory aspects, nanosystems form a distinctive group regarding their acceptance; relevant 
guidelines and relevant chapters of the European Medicines Agency (EMA) and U.S. Food and Drug 
Administration (FDA) must be applied during all manufacturing stages from material selection and 
formulation to the final production. Furthermore, the FDA has emphasized the application of the 
Quality by Design (QbD) methodology, which can be remarkably useful for the novel, high-risk 
dosage forms, and administration routes for careful planning and development even at the early phase 
of the research (FDA, 2019a). The adaptation of this method for the early development phase has also 
been published (Csóka et al., 2018). 
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2. AIMS  
The main aim of this study was to develop a nanosystem-based intranasal formulation of LOR. 
Based on the literature background of the nasal delivery, nanosuspension was selected to prepare the 
pre-dispersion for the nasal formulation. The applicability of a nanosuspension in a nasal formulation 
is a new approach in pharmaceutical technology, therefore few data for such systems are available up 
till now. QbD approach was implemented to set the critical process and material parameters that impact 
the preparation of nanosuspensions. A nasal formulation containing the nanosuspension of the poor 
water-soluble LOR was developed as liquid formulations based on using a mucoadhesive agent. The 
nasal delivery of nanosystem-based LOR is a novel strategy that could improve the bioavailability of 
LOR and introduce a new dosage form with high patient acceptance. 
Experimentally, the influential parameters were studied and optimized to develop the LOR 
nanosuspension as a pre-dispersion. For the final product, the concentrations of the drug and the 
mucoadhesive agent were investigated to finally evaluate the in vitro and in vivo characteristics of the 
prepared nanosuspension-based nasal formulation.  
The main steps in the experiments were the following: 
 Application of the extended QbD for research and development approach of nanosuspension as 
pre-dispersions containing LOR as H1 antihistamine agent. 
 Selection of the pre-dispersion of LOR to formulate a nasal product. 
 Evaluation of the pre-dispersions (nanosuspensions), and the dry nanoparticles by applying the 
related tests. 
 Performing in vitro and in vivo comparison studies of the nasal formulation. 
 Study the stability of the nasal formulation.  
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3. LITERATURE BACKGROUND 
3.1 Strategies to enhance the solubility of the poorly water-soluble drugs 
The progress in combinatorial chemistry research and high-throughput screening has led to 
introducing a vast number of poorly water-soluble drugs in the pharmaceutical pipeline. The non-
parenteral administration of the poor water-soluble API is associated with poor and variable 
bioavailability, whereas the parenteral delivery requires the use of high amounts of solubilizing 
excipients thus safety margins are compromised (Fahr and Liu, 2007).  
Different techniques and formulation strategies have been utilized to improve the solubility and the 
dissolution rate of poorly water-soluble drugs such as complexation with cyclodextrin derivatives 
(Davis and Brewster, 2004; Loftsson et al., 2004; McEwen, 2000), solid dispersions (Baghel et al., 
2016; Leuner and Dressman, 2000), micellar solubilization (Rangel-Yagui et al., 2005), 
microemulsions (He et al., 2010; Talegaonkar et al., 2008), and salt formation (Serajuddin, 2007).  
In addition to the conventional methods, tackling the solubility problems has become one of the main 
applications of nanotechnology in drug delivery. The most commonly used nanotechnology-based 
strategies in the development of delivery systems are divided generally into nanocrystals systems 
(nanosuspensions) (Agrawal and Patel, 2011), and nanostructured systems. The structured 
nanosystems of improved solubility and biopharmaceutical efficacy for poorly-water soluble drugs are 
nanoemulsions (Gorain et al., 2014), dendrimers (Milhem et al., 2000), self-emulsifying drug delivery 
system (Gursoy and Benita, 2004; Rahman et al., 2013), micelles (Satturwar et al., 2007), liposomes 
(Fenske et al., 2008; Prabhu et al., 2011), solid lipid nanoparticles (Venishetty et al., 2012), polymeric 
nanoparticles (Zhang et al., 2010), and carbon nanotubes (Wong et al., 2013). These nanosystems 
provide controlled and targeted drug delivery. 
The selection of the specific approach depends on the drug’s physicochemical properties such as 
intrinsic solubility and melting point, route of administration, as well as therapeutic requirements. 
3.2 Actualities of nanosuspension preparations 
Nanosuspension is an essential division of the nanotechnology geared mainly for pharmaceutical 
applications. EMA precisely defines nanomaterial as a natural or manufactured material containing 
particles, in an unbound state or as an aggregate or an agglomerate, where 50 % or more of the particles 
in the number size distribution, one or more external dimensions is in a size range 1-100 nm, or material 
has a specific surface area greater than 60 m2 cm-3 (EMA, 2006). On the other hand, the FDA has not 
set regulatory definitions for nanotechnology and nanomaterials but considers the engineering 
definition as materials that have at least one dimension in a size range of 1-100 nm (FDA, 2014). 
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Nanosuspensions are carrier-free dispersions of submicron drug particles stabilized by a minimum 
amount of ionic or steric stabilizer(s). Drugs in nanosuspension can exist in crystalline or amorphous 
forms (Müller et al., 1999; Müller and Peters, 1998; Sigfridsson et al., 2007).  
3.2.1 Methods of preparation of nanosuspensions  
The first generation of nanosuspension was nanocrystal and was chiefly produced by top-down and 
bottom-up techniques. The top-down method requires energy input to disintegrate the drug particles to 
the submicron level, such as milling. On the other hand, the bottom-up method depends on the 
assembling of the particles from the molecular state, as in precipitation (Junghanns and Müller, 2008). 
SmartCrystals® represents the second generation of nanocrystals. They have been created by the 
combination of the bottom-up and top-down methods. Consequently, new techniques have been 
introduced such as NanoEdge™ or H69 technologies that depend on microprecipitation followed by 
high-pressure homogenization (HPH) (Kipp et al., 2003; Müller and Möschwitzer, 2005), H42 that 
connects spray drying and HPH, and H96 technologies used freeze-drying and HPH (Möschwitzer and 
Andreas, 2006; Salazar et al., 2013). Combination technology has also been developed. It combines 
wet bead milling and HPH (Rolf, 2006). These new technologies can maximize particle reduction and 
overcome the limitations of the standard processes (Möschwitzer and Müller, 2006). The other new 
technology is NanoEdge™. This technology uses precipitation step with subsequent annealing step by 
applying high shear or thermal energy (Kipp et al., 2003). Fig.1 illustrates examples of the most 
commonly used methods for the preparation of nanosuspensions. 
Since the nanosuspension drug delivery system was firstly developed in 1994, nanosuspension has 
attracted attention as a formulation solution for poorly soluble drugs. Consequently, many 
nanosuspension products have been authorized and marketed. Table 1 lists examples of marketed 
pharmaceutical nanosuspensions products for different routes as different dosage forms. However, up-
to-date, there is no nanosuspension-based nasal dosage form in the market. 
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Table 1: Examples of marketed pharmaceutical nanosuspension-based products (Junghanns and 
Müller, 2008; Soares et al., 2018; Zhong et al., 2018). 
API Trade 
name 
Nanosuspension 
technology 
Route of 
administration  
Dosage form Indication  
Aprepitant Emend® Media milling Oral Capsule  Nausea and vomiting 
Fenofibrate  Tricor® Media milling Oral Tablet  Hypercholesterolemia 
Fenofibrate  Triglid HPH Oral Tablet  Hypercholesterolemia 
Griseofulvin  Gris-PEG® Coprecipitation  Oral Tablet Fungal infections 
Megesterol acetate Megace ES® Media milling Oral  Liquid 
nanosuspension 
Appetite stimulant 
Nabilone Cesamet® Coprecipitation  Oral  Capsule Nausea and vomiting 
Sirolimus  Rapamune® Media milling Oral  Tablet Immunosuppressant 
Paliperidone 
palmitate 
Invega 
Sustenna® 
HPH Parenteral Liquid 
nanosuspension 
Schizophrenia 
Paliperidone 
palmitate 
Invega 
Trinza® 
Media milling Parenteral Liquid 
nanosuspension 
Schizophrenia 
Aripiprazole 
Lauroxil 
Aristada® Media milling Parenteral Liquid 
nanosuspension 
Schizophrenia 
Naproxen sodium Naprelan® Media milling Oral Tablet Inflammation  
Morphine sulfate Avinza® Media milling Oral Capsule  Chronic pain 
Methylphenidate 
hydrochloride 
Ritalin LA® Media milling Oral Capsule Nausea and vomiting 
Aripiprazole Abilify 
Maintena® 
Media milling Parenteral Liquid 
nanosuspension 
Schizophrenia 
Dantrolene sodium Ryanodex® Media milling Parenteral Liquid 
nanosuspension 
Malignant 
hyperthermia 
 
Figure 1: The most common methods for the preparation of nanosuspensions. 
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3.2.2 Potential benefits of nanosuspensions  
The nanosuspensions offer many benefits that are milestones for this method. The followings 
represent the main advantages of the application of  nanosuspensions: 
a. Enhancement of dissolution rate and saturation solubility 
Size reduction of the particles is accompanied by a dramatic increase of the solute surface area, thus 
dissolution rate according to the Noys-Whitney model. Ostwald–Freundlich equation relates the 
saturation solubility to the dissolution pressure and radii of the particles. Accordingly, an increase of 
dissolution rate and saturation solubility are postulated by particle size reduction into the nanoscale 
(Noyes and Whitney, 1897; Wu and Nancollas, 1998). 
b. Development of various dosage forms 
Nanosuspensions can be further processed through granulating, layering, and developing of dry 
powder. Consequently, nanosuspension permits the production of different dosage forms with 
enhanced physicochemical properties. Tablets (Nekkanti et al., 2009), intravenous (Ben Zirar et al., 
2008; Ganta et al., 2009; Gao et al., 2010; Muller and Keck, 2004; Liu et al., 2010), pulmonary (Kraft 
et al., 2004; Shrewsbury et al., 2009; Yang et al., 2008), and nasal (Bhavna et al., 2014; Saindane et 
al., 2013) nanosuspension-based dosage forms have extensively been reported in the literature. 
c. Enhancement of mucoadhesive properties 
Nanosized particles possess a higher adhesion to the mucosal tissue than their large counterparties 
(Ponchel et al., 1997). 
d. Enhancement of stability 
Nanosuspension can protect the drug particles from the external environment and minimize the 
hydrolysis. On the other hand, the preservation of the crystalline structure promotes drug stability 
(Möschwitzer et al., 2004; Pu et al., 2009). 
e. Cost-effectiveness 
Nanosuspensions require a low amount of additives as a stabilizer, hence high drug loading can be 
achieved. The production processes are generally simple, adaptable, and scalable, thus facilitates large-
scale production for the market (Gao et al., 2013). 
On the other hand, particle size reduction is associated with agglomeration due to the high Gibbs free 
energy, whereas Ostwald ripening involves the dissolving of small particles followed by the deposition 
of the larger particles. Therefore, using surfactants or polymers is crucial to stabilize the nanocrystals 
(George and Ghosh, 2013; Kumar and Burgess, 2014; Lindfors et al., 2007; Tuomela et al., 2016). 
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3.2.3 Solvent-antisolvent precipitation - the commonly used bottom-up method 
Antisolvent precipitation is an effective bottom-up method for nanosuspension preparation. This 
method depends on changing the solubility of the drug in a water-miscible organic solvent by the 
addition of antisolvent that contains the stabilizers. Thus, drug particles covered by the stabilizer(s) as 
a consequence of the change of supersaturation are generated. This method is simple, cost-effective, 
and easy for scaling-up (Patravale et al., 2004; Rogers et al., 2004; Viçosa et al., 2012).  
Several factors affect the prepared nanosuspensions, such as solvent type, solvent: antisolvent ratio, 
stabilizer type, stabilizer concentration, drug amount, and drug: stabilizer(s) ratio (Hecq et al., 2005).  
Mostly, precipitation is assisted by ultrasonication for further particle size reduction and nucleation 
control (Anil et al., 2016; Bartos et al., 2015b). Moreover, drying procedures such as spray drying and 
freeze-drying are usually applied to produce stable dry nanoparticle and nanocrystals (Beirowski et al., 
2011; Chaubal and Popescu, 2008; Van Eerdenbrugh et al., 2008; Wu et al., 2011). 
In a multivariate production process, all the parameters of the different operations should be cautiously 
selected, and their effects on the final product must be assessed. In the case of preparing 
nanosuspension by precipitation ultrasonication, all the parameters related to these processes, in 
addition to the drying procedure, must be evaluated (Table 2) (Alshweiat et al., 2018). 
Table 2: The effects of different material and process parameters on the quality of attributes for 
the precipitation ultrasonication method (Alshweiat et al., 2019b). 
Parameter Justification 
Drug amount in the 
solvent phase  
An increase in drug concentration decreases the particle size due to increased saturation.This 
effect lasts until an optimum concentration above which particle size increases as drug 
concentration increases. 
Stabilizer type The proper type depends mainly on the affinity between the drug particles and the specific 
part of the stabilizer.  
Stabilizer 
concentration 
A sufficient amount is required to cover the nascent surface to prevent aggregation and 
agglomeration. However, a high concentration may form a viscous solution that can reduce 
solvent diffusion and affect ultrasonic wave transmission.  
Solvent: antisolvent 
ratio 
Particle size decreases by decreasing the solvent: antisolvent ratio due to increasing the degree 
of supersaturation. This reduction in particle size attains a constant value above a critical ratio. 
Antisolvent 
temperature 
A decrease in temperature generally reduces particle size and narrows particle size 
distribution. 
Sonication power Particle size usually increases with the increase of ultrasonic power input due to the increased 
erosion effect on the surface of large crystals and crystal agglomerates. However, if the energy 
exceeds a critical value, it increases the kinetic energy of particles and increases 
agglomeration. 
Sonication time  The optimal time length can support particle size reduction. The time effect is linked to the 
sonication power. 
Drying method Drying conditions have a critical impact on nanoparticle re-dispersibility. Optimal excipient 
type and quantities are required to ensure maximum stabilization. The drying rate also has 
significant effects on particle size. 
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3.3 Intranasal delivery as an alternative route of administration 
Poor aqueous solubility and dissolution rate and first-pass metabolism are the main limitations for oral 
administration. These factors inevitably produce poor and variable drug bioavailability. The parenteral 
administration (IV, IM, SC, and IP) offers high bioavailability. However, it is not a preferred route of 
administration due to factors related to safety and the patient's acceptance. Moreover, drug 
characteristics such as solubility and toxicity, have a crucial role in the preparation of parenteral dosage 
forms. Accordingly, other alternative routes of administration have been introduced, such as 
transdermal (Tanner and Marks, 2008), buccal (Patel et al., 2012), pulmonary (Patton, 2004), and 
intranasal delivery (Alshweiat et al., 2019a). 
Intranasal delivery (IN) has been introduced for systemic and brain drug delivery in addition to 
vaccination (Djupesland, 2013; Kushwaha et al., 2011; Li et al., 2013; Meredith et al., 2015; Vyas et 
al., 2005; Zaman et al., 2013). The advantages of IN delivery are related to the high surface area, high 
vascularization and permeation, and avoidance of the first-pass metabolism. For brain delivery, the IN 
route provides a direct nose to the brain pathway and circumvent the blood-brain barrier. Moreover, 
the IN route displays an efficient way for vaccine delivery (Fig.2).  
These factors introduced the nasal cavity as a suitable route for drugs that suffer from extensive first-
pass metabolism, poor solubility, and are degraded in the gastrointestinal tract. Therefore, the IN 
delivery is attractive for vaccines and peptides that are administered parentally so far. IN is a non-
invasive, nonsterile, and easily applied method. These aspects will increase patient acceptance and 
compliance (Costantino et al., 2007; Menzel et al., 2017). 
Several limitations can adversely affect the application and absorption of IN administered dosage form 
such as mucociliary clearance, limited volume of nasal administration (max. 200 µL), and presence of 
enzymes and efflux transporters. Moreover, the narrow nasal valve represents a potential hurdle for 
convenient drug delivery. On the other hand, pathological changes and environmental are also 
considered factors that affect the intranasal blood supply, hence the systemic absorption (Gizurarson, 
2015). 
Intranasal products with systemic effects are commercially available for certain drugs like 
zolmitriptan, sumatriptan, and fentanyl as well as peptides such as calcitonin, desmopressin, and 
nafarelin (Abboud et al., 1994; Dodick et al., 2005; El-Nemr et al., 2002; Gawel et al., 2005; Munjal 
et al., 2016; Nave et al., 2013; Nozaki et al., 2016; Winner et al., 2006). Other drugs have been nasally 
introduced for the treatment of urgent conditions such as migraine, seizures, opioid overdose, and pain 
breakthroughs in cancer. (Afridi et al., 2013; Corrigan et al., 2015; Graudins et al., 2015; Kapoor et 
al., 2014; Pavis et al., 2002; Steenblik et al., 2012). 
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Figure 2: The delivery purposes of the intranasal route of administration (Alshweiat et al., 2019a). 
 
In certain pathological conditions, nasal drug delivery is preferred over oral delivery, such as in the 
case of antihistamine for the treatment of allergic rhinitis. Allergic rhinitis is an inflammatory disease 
induced by allergen exposure and IgE-mediated inflammation that affects the upper respiratory tract 
and produces traditional symptoms of sneezing, itching, rhinorrhea, nasal congestion, and ocular 
symptoms of allergic conjunctivitis (Randall and Hawkins, 2018). It represents a global health problem 
affecting 10% to more than 40% of the population worldwide and highly recognized to have significant 
impacts on the quality of life, emotional well-being, sleep, social activity, and productivity. Therefore, 
allergic rhinitis is associated with a considerable economic burden (Blaiss et al., 2018; Rosenwasser, 
2002).  
Intranasal antihistamine effects have been noted on many mediators, including histamines, 
leukotrienes, cytokines, chemokines, mast cells, eosinophils, and neutrophils at clinically relevant 
concentrations. However, much higher concentrations (than routine dosing) of oral antihistamines are 
required to obtain any anti-inflammatory effects (Horak and Zieglmayer, 2009; Kaliner et al., 2011). 
The recommendations for using nasal antihistamines are based on the following; antihistamines are 
considered the first-line therapy for allergic and non-allergic rhinitis, they offer rapid onset of action, 
they are equal or superior to the oral antihistamines for the treatment of the seasonal rhinitis, they offer 
significant effects on nasal congestions, and they can achieve higher concentration to the target tissue 
(Berger et al., 2003; LaForce et al., 2004). Several studies have reported the efficacy of nasal 
antihistamines, compared to intranasal corticosteroids. Despite the superior effects of nasal 
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corticosteroids over the nasal antihistamines, both categories show an equal effect in reducing all 
symptoms of allergic rhinitis. Moreover, in short term studies, intranasal antihistamines showed a 
faster onset of action than intranasal corticosteroids (Kaliner et al., 2009; Meltzer et al., 1994). 
3.4 Innovation in nanosized-based intranasal delivery 
Innovations in nasal delivery have been raised by the applying nanotechnology to this route. 
Nanotechnology could address the limitations that are related to the physicochemical properties of the 
active agents as well as restrictions of the nasal delivery (Table 3) (Alshweiat et al., 2019a). 
Table 3: Nanotechnology solutions for intranasal delivery limitations (Alshweiat et al., 2019a). 
Limitation Nanotechnology effects 
Poor drug solubility  High ratio of surface area to volume. 
Providing interactions between the groups of the polymer and drug molecule by 
electrostatic and hydrogen bonding. 
Production of a microenvironment with specific low polarity inside the 
nanoparticles than in the aqueous bulk phase. 
(Chen et al., 2011; Devarakonda et al., 2004; Milhem et al., 2000; Pistolis et al., 
1999; Shrestha et al., 2014). 
Mucociliary clearance and short 
residence time 
Localization of the formulation for a longer time. 
Enhancement of contact time inside the nasal cavity. 
(Cui et al., 2006; Issa et al., 2005; Pawar et al., 2010). 
Poor penetration for large and 
hydrophilic molecules  
Ability to open up tight junctions. 
Possibility of high endocytosis.  
Ability to change mucosal membrane properties. 
(Bernocchi et al., 2016; Gao et al., 2006) 
Enzymatic activity  Encapsulation of liable molecules. 
(Kato et al., 1992). 
P-glycoprotein efflux transporter  Efficiency for bypassing and inhibition of P-glycoprotein.  
Chavanpatil et al., 2007; Shah et al., 2013). 
 
Recently, nanosuspensions have been introduced as competent solubility enhancement techniques, and 
newly have been emerged as a delivery system. Nanosuspension-based formulation with the nasal 
route has been proved for many purposes. The chief key is the selection of the proper dosage form that 
supports the localization of drugs at the nasal cavity for adequate time for drug absorption without 
being inhaled into the lungs. Therefore, nanoparticles must be incorporated into mucoadhesive 
formulations that maintain the nanosizing effects and prevent the inhalation of the particles (Alshweiat 
et al., 2019a). 
The knowledge of applying nanosuspension into nasal delivery has been reported in many studies. 
Saindane et al. (Saindane et al., 2013) incorporated a carvedilol-containing nanosuspension into in situ 
gel, Hao et al. (Hao et al., 2016) prepared resveratrol-based nanosuspension, and Gieszinger et al. 
(Gieszinger et al., 2017) formulated nanosized-based lamotrigine for brain delivery. Moreover, 
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meloxicam nanosuspensions have been produced for systemic delivery as a powder (Kürti et al., 2013) 
and sodium hyaluronate-based sprays (Bartos et al., 2015a). 
LOR is a class II agent according to the BCS, characterized by poor water solubility (3.03 μg mL-1) 
and high permeability (log P= 5). It is a weak base with a reported pKa value of 5.25 at 25 °C, 
responsible for its pH-dependent solubility and consequent variability in bioavailability (Ambrus et 
al., 2019; Dagenais et al., 2009; Han et al., 2004). Up-to-date, the nasal dosage form is not available 
on the market. Therefore, it could be advantageous to develop a nasal formulation based on 
nanosuspension of LOR to produce this agent in a new and novel dosage form. 
3.5 Formulation aspects of intranasal delivery  
Various aspects must be considered for the development and production of nasal formulations. For 
nanosystem-based formulations, the properties of the nanoparticles play a crucial role in nasal delivery 
from regulatory and industrial points of view. Moreover, customer voice must be included to develop 
nasal systems with high patient acceptance.  
3.5.1 Factors related to the properties of the nanoparticles 
The nanosized particles maintain distinctive physicochemical properties compared to their 
conventional counterparts. These properties are responsible for the nanoparticles' promising 
characteristics. The physicochemical characteristics of nanoparticles with significant effects on the 
nasal administration are size, shape, chemical composition, physicochemical stability, crystal 
structure/polymorphism, surface area, surface charge, and surface energy.  
Particle size is a critical evaluation parameter to assess the desired properties of nanoparticles due to 
its consequences on surface area and viscosity, and thus drug dissolution, release, absorption, and 
stability (Anantachaisilp et al., 2010). Due to their small size, nanoparticles are usually used as a drug 
carrier via passive transport, active transport, and endocytosis (Lockman et al., 2004; Shin et al., 2015). 
However, the mechanism by which nanoparticles enhance drug transport is not fully described. 
The surface charge also plays an essential role in the interactions of nanoparticles with biological 
systems. For example, positively charged nanoparticles have been designed to improve nasal adhesion 
with the nasal mucosa via the electrostatic interaction with the sialic groups of mucin (Alpar et al., 
2005).  
The shape of nanoparticles affects their stability, absorption, and cellular uptake. However, these 
effects are connected to the particle size and surface charge (Gratton et al., 2008).  
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3.5.2 Factors related to the properties of the active agent 
Physicochemical characteristics of the used drug profoundly affect its absorption and bioavailability 
following the nasal administration. 
a. Solubility and Dissolution Rate 
b. Lipophilicity 
c. Partition Coefficient and pKa 
d. Chemical form 
e. Polymorphism 
f. Molecular Weight 
3.5.3 Factors related to the properties of the formulation  
The properties of the nasal formulation have significant effects on the drug’s permeation and 
bioavailability, as well as satisfying application. 
a. Chemical reaction (pH) 
b. Osmolarity 
c. Viscosity  
3.5.4 Dosage forms of the nasal delivery  
The selection of dosage form depends upon the drug being used, proposed indication, patient 
population, and marketing preferences.  
a. Liquid dosage form 
The most simple and convenient systems developed for nasal delivery are solutions and suspensions.  
b. Gel dosage form 
Gels increase the contact time between the drug and the nasal mucosa due to their high viscosity. They 
also reduce the post-nasal drip and leakage of the formulation and reduce the irritation inside the nasal 
cavity. 
c. Powder dosage form 
Powders generally exhibit high stability. However, irritation is the major drawback of using powders 
in the nasal cavity. 
3.5.5 Factors related to the physiology of the nasal cavity 
a. Mucociliary clearance 
b. Enzymatic activity 
c. Nasal blood flow 
d. Pathological conditions 
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3.5.6 Additives of nasal formulations  
Various additives are required to promote the efficiency, safety, and acceptance of the nasal 
formulation. 
a. Permeation enhancers 
Permeation-enhancers are mainly studied to develop formulations for hydrophilic drugs of poor nasal 
membrane permeability. These agents enable the paracellular transport of hydrophilic and large 
molecules across the mucosal surface by opening tight junctions. The most used enhancing excipients 
are cyclodextrins and chitosan derivatives. These agents are biocompatible and induce the enhancing 
effects without causing damage to nasal mucosa (Illum, 2012; Rassu et al., 2018). 
b. Solubility enhancers 
Solubility enhancers are functional excipients used to enhance the solubility of the poorly water-
soluble drugs hence absorption and bioavailability such as cyclodextrins, dendrimers (Ghadiri et al., 
2019), and surfactants (Balakrishnan et al., 2004). 
c. Mucoadhesive agents 
Increase the contact time between the active agent and the nasal mucosa, thereby contributing to drug 
absorption. Many mucoadhesive agents have been used in nasal preparations such as carbomers, 
chitosan, alginate, Poloxamers, and sodium hyaluronate (Chaturvedi et al., 2011). 
d. Viscosity enhancing agents 
Viscosity enhancement is essential to localize the drug inside the nasal cavity. Moreover, entrapment 
of the drug in a viscous gel matrix can protect the drug from enzymatic degradation (Buwalda et al., 
2017; Warnken et al., 2016). 
e. Others 
Other excipients are required to improve the efficiency and safety of the nasal formulations such as 
buffers, osmolarity control agents, preservatives.  
The excipients must be compatible with the constituents of the formulations, used in small quantities, 
and of low toxicity. 
3.5.7 Nasal drug delivery devices  
The selection of the suitable delivery system depends on the dosage form, physicochemical properties 
of the drug, properties of the nasal formulation, the intended use, dosing accuracy, and marketing 
issues (Ali et al., 2010).  
For liquid dosage forms, the following devices are the most commonly used for nasal delivery. 
 Drops 
 Unit-dose containers 
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 Instillation and rhinyle catheter 
 Squeezed bottle 
 Airless and preservative-free sprays 
 Compressed air nebulizers 
 Metered-dose inhalers (MDIs) 
For powders, the following devices are commonly used. 
 Insufflators  
 Mono-dose powder inhaler 
 Multi-dose dry powder systems 
 Metered-dose aerosols 
The site of deposition and the deposition area depend on several parameters that are related to the 
delivery device such as mode of administration, geometry, and particle size of the formulation and 
velocity of the delivered particles. The traditional devices and pressurized metered-dose aerosols 
provide the dose of medication primarily to the anterior segment of the nasal passage. However, 
targeted delivery is highly required to deliver the active agent into the respiratory, trigeminal, and 
olfactory regions for systemic and brain targeting (Xi et al., 2016).  
New technologies have been introduced to overcome the inconveniences of the traditional nasal 
devices, improve systemic drug absorption, or to enable drug delivery to the brain through the olfactory 
area. Therefore, these emerging technologies, such as the bidirectional technology Optinose® 
(Djupesland, 2013), Controlled Particle Dispersion (CPD)® (Kurve) (Giroux et al., 2005), and 
Pressurized Olfactory Device (POD) (Hoekman and Ho, 2011) can widen and specify the intranasal 
delivery for efficient outcomes.  
Design parameters, such as the nosepiece shape, the flow rate, the particle size profile, and release 
angle can be adapted to optimize delivery to target sites beyond the nasal valve, avoid lung deposition, 
and to assure that particles are deeply deposited without exiting the contralateral nostril (Djupesland, 
2013). 
3.5.8 Patient expectations of intranasal delivery 
Patients -as users of the medicinal products- have an increasing role in therapeutic success. Identifying 
what is expected or is critical for patients and reflecting on these aspects during research and 
development is the first step to achieve patient acceptance and the required therapeutic outcome. This 
field has been ignored for many years, but as the effects of customers’ preferences increase, it should 
be considered more as part of R&D thinking (Hellings et al., 2012; Yanez et al., 2016). 
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Patient requirements have extended the need for safe and efficient drug delivery to other concerns such 
as the comfort of both formulation and applicator device in the nasal cavity, the ease of application, 
confidence in the delivered amount, and a warning about the remaining dose (dose counting). All these 
factors can enhance patients’ satisfaction and, therefore, their adherence. To improve efficiency and 
productivity, manufacturers must understand the best tools, methods, and analysis. They have to define 
their goals based on the patients’ opinions before proceeding into the production stage. Integrating the 
voice of the customer can help to assess the patients’ convenience for their product and induce 
manufacturers to develop patient-friendly products. These considerations have not been kept in the 
theoretical framework or companies, but have transferred to the regulatory agencies that seriously 
consider patients’ preferences and their assessments of using formulations and delivery devices 
(Alshweiat et al., 2019a). 
3.6 Quality by Design (QbD)  
QbD is a holistic, scientific, and risk-based approach of development, focusing on the understanding 
of the product and manufacturing process, starting with predefined objectives and controlling the used 
material and process to ensure the quality of pharmaceutical products (Yu, 2008). According to QbD, 
objectives, materials, methods, delivery systems, and expected outcomes should be identified clearly 
to end up with a product that can compromise between patients’ demands and industrial expectation 
alongside with the regulatory guidelines of the EMA or FDA (EMA,2001; FDA, 1998; 2002). In 2005, 
the FDA enforced the submission of QbD with new drug application requests. This proactive design 
offers the rewards of transferring the chemistry manufacturing control of the new abbreviated drug 
into the pharmaceutical quality assessment, thus saving the time of development and submission, 
saving the time of regulatory authorities’ approval, and defining the probability of out of specification 
and out of tolerance (Sangshetti et al., 2014). Three relevant documents were published as the 
International Council on Harmonization (ICH) guidelines describing the pharmaceutical development-
Q8, risk management-Q9, and quality system-Q10. The adoption of these guidelines provides immense 
potential for careful planning during formulation and development, even at the early stage of the 
research. Implementation of the QbD begins with determining the quality target product profile 
(QTPP) that describes information related to anticipated indications, route of administration, dosage 
form, and safety. This entails the identification of the critical attributes of the drug product that must 
be achieved to ensure the desired quality, considering the safety and efficacy of the drug product. 
The next step involves the identification of the relevant critical quality attributes (CQAs) that influence 
the QTPP in addition to the critical process parameters (CPPs) and critical material parameters (CMPs) 
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of high impacts on the CQAs. The selection of the CQAs, CPPs should be based on previous scientific 
experience and knowledge from relevant literature sources. 
Risk assessment (RA) is a principal part of QbD-based development. It assists in organizing the 
information to take the risk decision, thus saving time, cost, and efforts. The stage where RA must be 
applied throughout the research process is varied. Besides, it can be redefined and repeated (EMA, 
2015). Pallagi et al. (Pallagi et al., 2015) point out the importance of the risk assessment in the 
development of intranasal meloxicam nanosuspension at the early production stage.   
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4. MATERIALS 
a. Active agent 
Loratadine (LOR) was purchased from Teva (Budapest, Hungary). LOR shows a poor water solubility 
of 3.03 µg mL-1 and high permeability (log P 5.5). It is a weak basic agent with pka 5.25 at 25°C 
(Table 4). Therefore, LOR shows poor and variable bioavailability.  
Table 4: The properties of the active agent 
Chemical structure  
Molecular weight 382.888 g mol-1. 
Melting point 134-136 °C. 
Physical Description Solid-white crystal. 
Application  H1 antihistamine, used for the treatment of different allergic 
conditions. 
b. Excipients 
Different types of stabilizers have been used to prepare the nanosuspensions. On the other hand, a 
mucoadhesive agent was used to formulate the nanosuspension into nasal formulations (Table 5). 
Table 5: Properties and purchase data for the excipients used to prepare the loratadine nasal 
formulation. 
Excipient  Characterization  Role Purchase data  
Polyvinylpyrrolidine K-25 
(PVP K25) 
Linear hydrophilic polymer. Steric 
stabilizer 
ISP Customer Service 
GmBH (Cologne, 
Germany) 
Soluplus® Polyvinyl caprolactam–polyvinyl acetate–
polyethylene glycol. It acts as a stabilizer and 
a solubilizing agent in the formulations of 
poorly water-soluble drugs. 
Steric 
stabilizer  
BASF 
(Ludwigshafen, 
Germany) 
Poloxamer 188 (F68) Nonionic triblock copolymer composed of a 
central hydrophobic chain of 
polyoxypropylene (poly(propylene oxide)) 
flanked by two hydrophilic chains of 
polyoxyethylene (poly(ethylene oxide)). 
Steric 
stabilizer 
BASF 
(Ludwigshafen, 
Germany) 
Tween 80 Polyoxyethylene sorbitan monooleate is a 
non-ionic surfactant. 
Steric 
stabilizer 
Fluka Chemika 
(Buchs, 
Switzerland) 
Sodium lauryl sulphate 
(SLS) 
Anionic surfactant. Anionic 
stabilizer 
FreeHand Ltd. (Pecs, 
Hungary) 
Hydroxypropylmethylcell
ulos (HPMC) 
Semisynthetic cellulose derivative. Steric 
stabilizer 
Colorcon 
(Budapest, Hungary) 
Sodium hyaluronate  Linear polysaccharide polymer. It is 
biocompatible, biodegradable, and non-
immunological material. 
Mucoadhesive 
agent 
Gedeon Richter Plc. 
(Budapest, Hungary) 
Trehalose dihydrate 
(TRE) 
Sugar, consisting of two units of glucose, used 
to stabilize molecules during both freezing 
and drying. 
Cryoprotectant Sigma-Aldrich (New 
York, USA) 
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5. METHODS 
5.1 Determination of QbD elements for producing LOR nanosuspension 
QTPP, CQAs, CMPs, CPPs were determined for producing loratadine nanosuspension (LNS), 
based on prior knowledge, previous studies, preliminary experiments, and data from relevant literature.  
Particle size, polydispersity, and zeta potential were selected as CQAs for the nanosuspension. For the 
freeze-dried nanoparticles (DLNS), particle size, polydispersity index, solubility, and dissolution 
properties were determined as CQAs. The RA was performed with Lean QbD Software® (2014QbD 
Works LLC., Fremont, USA). According to this software, the connections between CQAs and CPPs 
were evaluated and rated on a three-level scale. This scale reflects the impact of their interaction on 
the product as high (H), medium (M), or low (L). The dynamism of this interdependence rating is 
presented in tables generated by the software. This was followed by the probability rating step, in 
which CPPs were estimated and categorized on a 10-point scale. Further, Pareto charts were generated 
by the software, presenting the numeric data and the ranking of CQAs and CPPs (Pallagi et al. 2015). 
5.2 Preparation of LOR nanosuspensions  
5.2.1 Preparation of loratadine nanosuspensions (LNSs) 
LNSs were prepared using the precipitation-ultrasonication method. LOR was dissolved in ethanol 
according to its solubility, while the stabilizer(s) was (were) dissolved in water. For the mixtures of 
stabilizers, one was added to the solvent phase, while the other one was added to the antisolvent phase 
(Fig.3). Both solutions were filtered through a 0.45 μm filter (FilterBio PES Syringe Filter, Labex Ltd., 
Budapest, Hungary). The fresh-made LOR solution was rapidly introduced into the cool antisolvent 
under sonication using a UP 200 s Ultrasonic processor (HielscheruUltrasonics GmbH, Germany) and 
different conditions in terms of energy power, sonication time and sonication temperature. The 
temperature of sonication was controlled (Julabo F32, JULABO GmbH, Germany). The prepared 
nanosuspensions were stirred at room temperature for 24 h to remove the organic solvent. 
 
Figure 3: Schematic illustration of the contents of the solvent and antisolvent phases of LNSs. 
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5.2.2 Preparation of nanosuspensions related physical mixtures 
Physical mixtures (PMs) corresponding to the composition of the nanosuspensions were prepared as 
reference samples by blending LOR with the suitable excipients in a Turbula mixer (Turbula System 
Schatz; Willy A. Bachofen AG Maschinenfabrik, Basel, Switzerland) using 60 rpm for 10 min. 
5.3 Preparation of loratadine nasal formulations (NFs) 
The intranasal formulations (NFs) were prepared from the nanosuspensions (pre-dispersions). These 
pre-dispersions were prepared by using 1 mL of the solvent phase contained 200 mg of LOR in ethanol 
and 40 mL of 0.2% w/v F68 as the antisolvent under the specified process conditions of 30 min 
sonication time, 4 °C sonication temperature, and 50% sonication amplitude. The pre-dispersions were 
stirred for 24 h to remove ethanol. Afterward, HA was added to prepare the nasal formulation. The 
final concentrations of the formulations were controlled by dilution with 0.2%, w/v F68. NFs were 
stored in a refrigerator at 4 °C for 24 h to ensure the complete solvation of the polymer. For 
comparison, reference samples (REF) were prepared. Table 6 shows the final concentrations of LOR 
and HA in the prepared nasal formulations and corresponding reference samples that contained the 
same amount of LOR and HA in 0.2%, w/v F68. However, the LOR in the reference samples was 
added without any processing. The REF samples were prepared by mixing raw LOR powder with HA 
and 0.2% F68 solution, using ULTRA-TURRAX® homogenizer at 5000 rpm for 10 min (GmbH, 
Germany). 
Table 6: Concentrations of LOR and HA (mg mL-1) in the HA-based nasal 
formulation and reference samples (Alshweait et al., 2020). 
Sample LOR (mg mL-1) HA (mg mL-1) 
NF1 1 1 
NF2 1 5 
NF3 2.5 1 
NF4 2.5 5 
REF1 1 1 
REF2 1 5 
REF3 2.5 1 
REF4 2.5 5 
 
5.4 Micrometric characterization of nanosuspensions and dry nanoparticles 
Selected LNSs were dried to obtain solid products to study the physicochemical and investigate the 
biocompatibility. The LNSs were dried by vacuum oven at 25 °C for 24 h and freeze-drying in a 
Scanvac, CoolSafe 100-9 Pro type apparatus (LaboGeneApS, Lynge, Denmark). In freeze-drying, the 
nanosuspensions were lyophilized with 5% w/v trehalose (TRE) to -40°C. 
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Scanning electron microscopy (SEM) (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan) was used 
to characterize the morphology of the LOR, PMs, and dry nanoparticles. The samples were coated 
with gold-palladium using a sputter coater (Bio-Rad SC 502, VG Microtech, Uckfield, UK) under an 
electric potential of 10.0 kV at 10 mA for 10 min. The air pressure was set to 1.3–13.0 mPa. 
The mean particle size (MPS), zeta potential (ZP), and polydispersity index (PDI) of LNSs were 
measured by laser diffraction using a Malvern Nano ZS zetasizer (Malvern Instrument, UK), using 
water as the dispersant and setting the refractive index to 1.62. 12 parallel measurements were carried 
out. 
5.5 Structural analysis of the dry nanoparticles 
The structures of LOR, raw material, and dry nanoparticles were characterized using a BRUKER D8 
Advance X-ray powder diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) with Cu K λI 
radiation (λ = 1.5406 Å) and a VÅNTEC-1 detector. Powder samples were scanned at 40 kV and 40 
mA, with an angular range of 3° to 40° 2θ, at a step time of 0.1s and a step size of 0.01°. Eva software 
was used to separate the crystal and related amorphous peaks. Thus, the software calculated the values 
of the integrated intensities of the amorphous and crystalline contribution and the crystalline-only 
contribution. The crystallinity index values (Xc) of the samples were calculated based on the following 
equation: 
Xc =
𝐴𝑐𝑟𝑦𝑠𝑡𝑎𝑙𝑙𝑖𝑛𝑒
𝐴𝑐𝑟𝑦𝑠𝑡𝑎𝑙𝑙𝑖𝑛𝑒 + 𝐴𝑎𝑚𝑜𝑟𝑝ℎ𝑜𝑢𝑠
∗ 100     (1) 
Thermal analysis of the samples was carried out using a differential scanning calorimeter (Mettler 
Toledo DSC 821e, Mettler Inc., Schwerzenbach, Switzerland). About 3–5 mg of powder was 
accurately weighed into DSC sample pans, which were hermetically sealed and lid pierced. An empty 
pan was used as a reference in an inert atmosphere under constant argon purge. The samples were 
analyzed in the temperature range of 25–300 °C at a heating rate of 5°C min-1. 
FT-IR spectra of raw materials and the prepared samples were obtained by Fourier-transform infrared 
spectroscopy (Thermo Nicolet AVATAR 330, USA) equipped with the GRAMS/AI ver. 7program. 
Samples were grounded and compressed into pastilles with 150 mg dry KBr. The pastilles were 
scanned 128 times at a resolution of 4 cm-1in the wavenumber region 4000–400 cm-1. 
5.6 Saturation solubility of the dry nanoparticles 
Saturation solubility of the samples was investigated by adding excess amounts of the sample into 5 
mL of water, PBS (pH 7.4), or PBS (pH 5.6) at 25ºC. Next, the suspensions were filtered, and the drug 
concentrations in the filtrate were measured by UV spectroscopy at ƛmax 248 nm. 
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5.7 Drug content and dissolution behaviours of the dry nanoparticles 
The LOR content of the sample was determined by dissolving 10 mg of the dry nanoparticles in 50 
mL of 0.1N HCl. After stirring the solution with a magnetic stirrer (400 rpm) at room temperature for 
24 h, it was filtered and analyzed. The concentration was measured spectrophotometrically at 248 nm. 
The modified paddle method (USP dissolution apparatus, type II Pharma Test, Hainburg, Germany) 
was used to characterize the dissolution rates of LOR, PMs, and DLNs. 1.11 mg of pure LOR or DLN 
equivalent to 1.11 mg of LOR in 100 mL PBS, pH 7.4 was used. The paddles were rotated at 100 rpm 
at 37°C. 5 mL aliquots were taken at 5, 10, 15, 30, 60, 90, and 120 min and were filtered. 
Concentrations of LOR were measured spectrophotometrically (Unicam UV/VIS Spectrophotometer, 
Cambridge, UK) at ƛmax 248 nm. The calibration curve was taken in the concentration range of 2–20 
μg mL-1. The calibration curve was linear throughout the whole range tested and was described by the 
equation A = 0.0388 conc. (R2 = 0.9997) (Alshweiat et al., 2018). 
Dissolution efficiency (DE) of the samples was determined by calculating the percentage of the ratio 
of the area up to time t divided by the area that described 100% dissolution at the same time (Khan, 
1975). 
%𝐷𝐸 =
∫ 𝑦 𝑋
𝑡
0
 𝑑𝑡
𝑦100 𝑋 𝑡
× 100%                 (2) 
Relative dissolution (RD) concerning the raw LOR at 60 minutes was calculated using the following 
formula: 
𝑅𝐷 60 𝑚𝑖𝑛 =  
% 𝐷𝐸60 𝑚𝑖𝑛
%𝐷𝐸 60 min 𝐿𝑂𝑅
         (3) 
The trapezoidal method was used to calculate the area under the curve (AUC). AUC is the sum of all 
trapezia: 
𝐴𝑈𝐶 =  ∑
(𝑡1 − 𝑡𝑖−1)(𝑦𝑖−1 + 𝑦𝑖)
2
𝑖=𝑛
𝑖=1
       (4) 
Where ti represents the time point, and yi is the percentage of sample dissolved at time ti. Mean 
dissolution time (MDT) was calculated as follows (Costa, P., & Lobo, 2001): 
𝑀𝐷𝑇 =
∑ 𝑡𝑚𝑖𝑑∆ 𝑀
𝑛
𝑖−1
∑ ∆ 𝑀𝑛𝑖−1
                       (5) 
Where i is the dissolution sample number, n is the number of dissolution times, tmid is the time at the 
midpoint between times ti and ti−1, and ∆M is the amount of LOR dissolved (mg) between times ti and 
ti−1. 
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5.8 Characterization of the nanosuspension-based nasal formulations (NFs) 
5.8.1 pH and drug loading of the nasal formulations 
The pH of the nasal formulations was measured by transferring 1 mL of the formulation into a 10 mL 
volumetric flask. The solution was diluted with distilled water. The pH of the resulting solution was 
determined using a digital pH meter (Inolab, pH 7116, Xylem Analytics Germany GmbH, Germany). 
The drug loading of the nasal formulation was measured by dissolving 300 mg of the formulation 50 
mL of 0.1N HCl, pH 1.2. The mixture was stirred for 24 h at 37 ± 0.5 °C. The mixture was filtered, 
and the drug content determined by using a UV–visible spectrophotometer (Unicam UV/VIS) at ƛmax 
248 nm. Accordingly, the percent of drug loading was calculated from the ratio of practical and 
theoretical drug amount. 
5.8.2 Rheological measurements of NFs 
Rheological measurements were performed at 37 ºC with a Rheostress 1 Haake instrument (Karlsruhe, 
Germany). A cone-plate device was used where the cone angle was 1°, the thickness of the sample 
was 0.052 mm, and the diameter of the device was 6 cm. The flow curves of the samples were plotted 
under the shear rate range of 0.01 to 100 s-1. 
Rheology is one of the accepted methods to characterize mucoadhesive behaviours (Hassan and Gallo, 
1990). Rheological synergism between mucin and the observed systems can be considered as an in 
vitro parameter to determine the mucoadhesive behaviour of systems. This viscosity change, called 
the bioadhesive viscosity component (ηb), is caused by chemical and physical bonds formed in 
mucoadhesion. It can be calculated as follows: 
ƞb = ƞ𝑡 − ƞ𝑚 − ƞ𝑝              (6) 
Where ƞt is the viscosity of the combination of NF with mucin, ƞm, and ƞp are the viscosities of the 
mucin and NF, respectively (Thirawong et al., 2008). 
For mucoadhesivity, NFs were stirred with mucin (M) for 3 h before the measurement. The final 
concentration of M in the samples was 5% w/w. Moreover, the viscosity of the NFs and the 
combination with mucin were measured. 
5.8.3 In vitro studies of the selected NF 
In vitro release was carried out in a dialysis bag in artificial nasal fluid (ANF) media contained 8.77 
mg mL-1 NaCl, 2.98 mg mL-1 KCl, and 0.59 mg mL-1 CaCl2 at pH 5.6 (Xie et al., 2019). 300 mg of the 
NF and corresponding reference were loaded into a dialysis bag and dialyzed against 100 mL of the 
dissolution medium at 37±0.5 °C and under 100 rpm paddle speed. At predetermined intervals, 5 mL 
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aliquots were withdrawn and replaced with an equal volume of fresh dissolution medium. The samples 
were filtered through a 0.45-μm filter and analyzed by a UV spectrometer at ƛmax 248 nm.  
Permeability studies were executed using a vertical Franz diffusion cell system (Logan Instrument 
Carporation, NJ, USA). 300 mg of NF was placed on the polyvinylidene fluoride synthetic membrane 
(Durapore1 Membrane Filter, EMD Millipore, Billerica, MA, USA). The membrane was impregnated 
with isopropyl myristate. The actual diffusion surface was 1.72 cm2. Phosphate buffer (PBS, pH 7.4, 
37 °C) was used as an acceptor phase (7 mL). The rotation of the stirring bar was set to 300 rpm. At 
predetermined time points of diffusion, 0.8 mL samples were taken from the acceptor phase by the 
autosampler (Hanson Microette Autosampling System, Hanson Research, Chatsworth CA, USA) and 
were replaced with a fresh receiving medium. The amount of LOR diffused was determined 
spectrophotometrically.  
The flux (J) of the drug was calculated from the quantity of LOR that permeated through the 
membrane, divided by the surface of the membrane insert and the duration [mg cm-2 h-1] using the 
following equation. 
J =
m
At
                                        (7) 
The permeability coefficient (Kp, cm h-1) was determined from J and the initial concentration of the 
drug in the donor phase (Cd [mg cm-3]): 
Kp[cm/h] =
J
Cd
                    (8) 
5.8.4 In vivo studies of the selected NF 
a. Drug administration using rat’s model 
The experimental protocols and animal care methods were approved by the National Scientific Ethical 
Committee on Animal Experimentation (permission number IV/1247/2017). The animals were treated 
following the European Communities Council Directives (2010/63/EU) and the Hungarian Act for the 
Protection of Animals in Research (Article 32 of Act XXVIII). 
Single-dose in vivo studies were designed in male Sprague-Dawley rats weighing 220-250 g. The rats 
were divided into 4 groups of 4 animals each. Each rat received a dose of 0.5 mg kg-1 of LOR. For the 
first group, 50–62 μL of the selected NF was administered intranasally to each rat via a 100 μL pipette 
into the nostrils. For the second group, the rats were nasally given the corresponding REF sample. The 
rats were anesthetized using 50 mg kg-1 isoflurane for 5 min before the nasal administration. 
For oral dosing, the third and fourth groups received the selected NF sample and the corresponding 
REF sample, respectively. The samples were mixed with distilled water to increase the volume to 1 
mL containing 0.5 mg kg-1 of LOR and were administered by gastric lavage.  
24 
 
0.5 mL of blood was collected from the tail vein at 0.5, 1, 2, 3, 4, 8, 12, and 24 h post-dosing. The 
blood samples were transferred into Eppendorf tubes containing sodium ethylenediaminetetraacetate. 
The samples were centrifuged at 1,500 g for 10 min at 5 °C. The separated plasma samples were stored 
at -80 °C until analysis. 
b. Plasma Sample preparation 
LOR was isolated from plasma samples by a liquid-liquid extraction procedure. To 100 µL of plasma, 
10 µL ACN: H2O, (1:1, v/v), 10 µL of 3M NaOH, and 20 µL of d5-Loratadine (d5-LOR) −stable 
isotope-labelled internal standard (15.0 ng mL-1, in ACN:H2O, 1:1, v/v)− were added. The mixture 
was vortexed and shaken for 10 min at room temperature with 1 mL of n-hexane on a horizontal shaker, 
then centrifuged for 10 min at 3,000 rpm at 4°C to obtain the clear organic layer. 800 µL of the upper 
organic phase was transferred into a 1.5 mL glass vial, evaporated to dryness under a gentle stream of 
nitrogen and reconstituted in 100 µL starting eluent (5 mM ammonium acetate (pH = 5):ACN, 6:4, 
v/v). 20 µL was injected into the LC-MS/MS system for analysis. 
c. Preparation of the calibration curve 
The calibration curve for the quantification of LOR was set up in drug-free rat plasma. For the 
preparation of standard points, 100 µL rat plasma, 10 µL LOR standard solution (0.7–30.0 ng mL-1, 
diluted in ACN:H2O, 1:1, v/v), 10 µL 3M NaOH, and 20 µL d5-Loratadine (15.0 ng mL
-1) were mixed 
and treated as above. 
d. LC - MS/MS Analysis of LOR 
The quantitative analysis of LOR was performed by using a Waters Acquity I-Class UPLCTM system 
(Waters, Manchester, UK), connected to a Q ExactiveTM Plus Orbitrap mass spectrometer (Thermo 
Fisher Scientific, San Jose, CA, USA) equipped with a heated ESI ion source (HESI-II). 
Chromatographic separation was performed at 25 °C column temperature, on an ACE CN column (50 
mm × 2.1 mm, particle size 3.0 µm) protected by an ACE CN guard column (Advanced 
Chromatography Technologies, Aberdeen,  Scotland) by using 5mM of ammonium-acetate (pH = 5) 
as Solvent A and acetonitrile as Solvent B. Gradient elution program (started and maintained at 40% 
B for 1 min, increased linearly to 100% B in half min, kept at 100% B for 1.5 min, dropped back to 
40% B in 0.1 min and kept there for 1.9 min for equilibration) with a flow rate of 300 µL min-1 was 
applied to elute the analyte. 
The mass spectrometer was used in positive mode with the following parameters of the HESI-II source: 
spray voltage at 3.5 kV, capillary temperature at 253 °C, aux gas heater temperature at 406 °C, sheath 
gas flow rate at 46, aux gas flow rate at 11, sweep gas flow rate at 2, S-lens RF level at 50.0 (source 
auto-defaults). Data acquisition was performed in parallel-reaction-monitoring (PRM) mode by 
monitoring the transitions of m/z 383→337 (LOR) and m/z 388→342 (d5-LOR) as quantifier and m/z 
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383→267 (LOR) and m/z 388→272 (d5-LOR) as qualifier ions. The collision energy (CE) for specific 
quantitation was optimized to maximize sensitivity and proved to be 28 eV for LOR and its stable 
isotope-labelled form, too. A valve placed after the analytical column was programmed to switch flow 
onto MS only when analytes of interest elute from the column (1.4–2.4 min) to prevent excessive 
contamination of the ion source and ion optics. Washing procedures of the autosampler before and 
after injecting samples were programmed to avoid carry-over of analytes. 
Data acquisition and processing were carried out using Xcalibur and Quan Browser Software (Thermo 
Fisher Scientific, San Jose, CA, USA).  
e. Statistical analysis 
The statistical analysis was performed with Prism 5.0 software (GraphPad, San Diego, CA). The 
results are shown as the mean ± SD. The statistical methods included Student's t-test (two-group 
comparison). A probability (P) of less than 0.05 was considered statistically significant (*P < 0.05). 
The calculation of area under the curve (AUC) of the time (min) – concentration (nmol L-1) curves of 
each group of animals were performed with PKSolver add-in of Microsoft Excel (MS Office 2010) 
using non-compartmental analysis of data after extravascular input (model #101) of LOR (Zhang et 
al., 2010). The AUC values were calculated using the linear trapezoidal method. 
5.8.5 Stability assessment of the selected NF  
Stability studies of the selected NF were carried out by visual inspection. Stable systems were 
identified to be free of any physical changes such as phase separation, flocculation, or precipitation. 
Stability was observed at temperatures of 4 ºC and 25 ºC for 6 weeks. Moreover, the formulations were 
evaluated for particle size, polydispersity index, zeta potential, and drug content. 
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6. RESULTS  
6.1 QbD and Knowledge space of LNS-based product 
The development of knowledge space could visualize the overall manufacturing process for 
the selection of CPPs, and the definition of the required CQAs (Csóka et al., 2018). The first step was 
setting up an Ishikawa (fishbone) diagram, including all the parameters influencing the desired 
nanosuspension-based product containing LOR for nasal administration. Ishikawa diagram could list 
the parameters of significant effects on the target product into four groups;1. material characteristics, 
2.production method, 3.investigation method, and 4. therapeutic and regulatory aspects (Fig.4).  
The characteristics of the API, such as solubility, melting point, and lipophilicity, must be identified 
to set the targets of the preparation. Moreover, the properties of the excipients such as lipophilicity, 
viscosity, and their effects on the drug’s solubility play a crucial role in the production of stable 
nanosuspensions (Obeidat and Sallam, 2014; Verma et al., 2009). 
The production method critically affects the particle size distribution. Ishikawa could help in defining 
the CPP and performing the risk assessment alongside the QbD (Kola Srinivas et al., 2016). 
The most significant characterization parameters of nanosuspension are particle size and particle size 
distribution. These parameters determine the physicochemical properties of the nanoparticles, such as 
solubility, dissolution behaviour, and physical stability. Moreover, the shape of the nanoparticles 
(nanocrystals) is an important parameter that has consequences on the drug’s permeability (Müller et 
al., 2001). Thermal and structural analysis with DSC, XRPD, and FTIR are essential to determine the 
polymorphic changes, crystallinity status, the structure of the active agent, effects of the production 
methods on the structure of the drug, and interactions between the active agent and the excipients 
(Chogale et al., 2016; Pinna, 2005). Improved solubility and dissolution are the ultimate targets of 
developing the nanosuspension of the poorly water-soluble drugs, and therefore, these analyses are 
vital to check the achievement of these aims (Gigliobianco et al., 2018). 
For nasal formulations, determination and investigation of the drug release and absorption must be 
assessed. The preset goals determine the required examinations. Moreover, based on RA, experiments 
that can evaluate the CQAs must be of higher priority (Pallagi et al., 2015). 
The next step was to select the elements of QTPPs, CQAs, CMPs, and CPPs for the aimed nasal 
product. Table 7 lists these elements alongside with justification and explanation for the selected 
factors.  For adaptation to the QbD-based development principles, QTPP and the required CQAs were 
defined. 
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Figure 4: Ishikawa diagram illustrating the parameters influencing the quality of the NF containing 
nanosized LOR. 
Table 7: QTPP, CQAs, CMP, and CPPs of LOR nanosized-based nasal formulation. 
Explanation Justification Target  
QTPP 
The therapeutic 
indication is a suggested 
QTPP by the ICH Q8. 
LOR is a second-generation H1 
receptor blocker used for the treatment 
of different allergies without CNS 
effects. 
Histamine H1 receptor 
antagonist 
Therapeutic indication 
The patient target is a 
suggested QTPP by the 
ICH Q8 clinical setting. 
LOR is administered for a short time 
until the symptoms clear up or 
regularly during the seasons of allergy. 
It is not recommended for children 
younger than 2-years old. It is 
pregnancy category B, and it is not 
recommended during lactation. 
Adult and children Target patient population 
The route of 
administration is a 
suggested QTPP by the 
ICH Q8. 
Avoidance of pH-dependent 
absorption of LOR, highly 
vascularized, highly absorption, 
noninvasive, easy to administrate. 
Nasal  Route of administration  
The site of activity is 
critically related to drug 
quality, efficacy, and 
being a QTPP 
requirement. 
Absorption through the nasal mucosa 
into the blood circulation. 
Systemic  Site of activity  
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The dosage form is 
suggested to be a QTPP 
part by the ICH Q8. 
Nanosized particles increase the 
dissolution and solubility of LOR, 
enhance the bioadhesive properties, 
increase the absorption into the 
systemic circulation. 
Nasal viscous 
formulations contain 
nanosized LOR  
Dosage form 
The dissolution profile 
is critically related to the 
quality and efficacy of 
the administered drug. It 
is suggested to be a 
QTPP part by the ICH 
Q8. 
Dissolution affects the bioavailability 
and pharmacokinetics of the product. 
Enhanced dissolution rate Dissolution profile 
Precipitation is a cost-
effective process that 
efficiently leads to 
particle size reduction to 
the nano-range. 
Effective, simple, and low cost of 
production.  
Precipitation  Production  
CQAs 
Critically related to 
product quality and 
safety. 
 
Ionic and polymeric stabilizers are 
used to prevent the aggregation and 
growth of the nanoparticles. 
The mucoadhesive polymer (HA) is 
used to increase the residence time of 
the formulation in the nasal cavity, and 
to enhance drug permeation.  
The organic solvent is used as a solvent 
to prepare the nanosuspension by the 
antisolvent precipitation.  
TRE is used as freeze-drying 
cryoprotectant.  
F68, Tween 80, PVP, 
HPMC, SLS, Soluplus® 
HA 
Ethanol 
TRE 
Excipients  
Critically related to 
efficacy by its impact on 
drug dissolution and 
solubility. 
Nanosize dimensions increase the 
surface area, enhance solubility, 
dissolution, and diffusion of the LOR 
through the nasal mucosa. 
Nanosize Homogenous 
product 
(300-500 nm) 
Size/ surface area  
The dosage form is a 
suggested QTPP by the 
ICH Q8. 
Nanoparticles suspended in a 
mucoadhesive formulation for 
maximum distribution and absorption.  
Viscous liquid 
formulation  
Dosage form  
Critically related to the 
efficacy and quality, it 
affects the 
bioavailability and 
pharmacokinetics.  
Dialysis was used to evaluate in vitro 
dissolution in artificial nasal fluid 
media. 
High drug release 
(in 15 min) 
Dissolution  
Critically related to 
safety. 
Non-toxic and biocompatible agents 
were used. 
Non-toxic, and non-
irritative. 
Toxicity  
Critically related to 
efficacy and stability. 
The amorphous status has a higher 
dissolution, but lower stability than the 
crystalline form. 
Amorphous. 
Crystalline. 
Structure 
(amorphous/crystallinity) 
Critically related to the 
efficacy, affect the 
administration route, 
and the bioavailability. 
Permeability was evaluated by in vitro 
diffusion through Franz diffusion cell. 
Effective absorption. Permeability  
Critically related to 
efficacy and safety. 
The viscous formulations should 
preserve the homogenous distribution 
of the nanosized particles. 
No visible signs of 
aggregation or separation.  
Stability  
CMPs-CPPs 
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Critically related to 
efficacy, safety, and 
quality. 
Amount and type of stabilizer 
additives. These factors influence 
water solubility, amorphous, and 
crystalline structure of the used 
API.Different drug amounts (50, 75, 
100, and 200 mg), stabilizer 
concentration (0.2, 0.4, and 0.6%, 
w/v), HA (1 mg mL-1 and 5 mg mL-1) 
were tested. 
Stabilized, enhanced 
dissolution rate, and 
increased mucosal 
resident of the nasal 
product. 
Composition (Excipients, 
ratios, additives) 
Critically related to 
efficacy and quality. 
10, 20, and 30 min of sonication 
periods were tested. 
Decreased particle size.  Sonication time  
Critically related to 
efficacy and quality. 
25 and 4 °C temperatures were tested. Affected particle size 
reduction. 
Sonication temperature  
Critically related to 
efficacy and quality. 
30, 50, and 100% amplitudes were 
tested. 
Decreased particle size Sonication power  
Critically related to 
efficacy and quality. 
Freeze drying conditions, including 
type and concentration of the 
cryoprotectant, temperature, pressure, 
and time. 
Stabilized the particle 
size.  
Freeze-drying 
parameters  
 
RA reveals the interdependence rating between the QTPP and CQAs, and between CQAs and the 
CPPs-CMPs. The interactions were ranked on the three-level scale of high (H), medium (M), and low 
(L) (Fig.5). 
 
Figure 5: Results of RA-based of (a) interdependence rating between QTPP and CQAs, and (b) 
CQAs and CPPs-CMPs. 
Furthermore, the severity scores for each of the critical parameters were selected and presented on a 
Pareto chart (Fig.6). Pareto charts also give a graphical overview of the hierarchy of CQAs and CPPs 
as the height of each bar gives information about the significance of the variables.  
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Figure 6: Pareto charts of (a) the CQAs and (b) CPPs-CMPs with calculated numeric severity 
scores. 
Fig.5a shows the high impacts of size and surface area on the route of administration, site of activity, 
selection of the dosage form, and dissolution. Dissolution, in turn, was highly affected by the surface 
area and the structure. Moreover, permeability had significant effects on the route of administration, 
site of activity, and dosage form. On the other hand, toxicity had significant impacts on the indication, 
route of administration, and activity. The effects of particle size on dissolution have been documented 
as small particles have higher dissolution than the large particles (Noyes and Whitney, 1897). Apart 
from this, excipients have a major role in the safety and efficiency of the nasal administration. 
Therefore, the selection of suitable non-toxic, and non-irritative excipients, is significant for producing 
efficient and safe nasal products. The excipients must guarantee the production of nano-sized particles 
that are stable to increase the surface area and enhance the dissolution rate. Moreover, the effects of 
the excipients on permeability must be considered. 
Accordingly, particle size, polydispersity, solubility, and dissolution were classified as first-line 
priority CQAs (Fig.6a). Therefore, practical research was focused on developing nasal formulations 
displaying appropriate CQAs (Alshweiat et al., 2018; Alshweiat et al., 2019b). 
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Fig.5b shows that the particle size, polydispersity index, zeta potential, structure, stability, solubility, 
and dissolution rate were highly influenced by drug concentration, stabilizer type and concentration, 
and sonication time, power, and temperature. As for freeze-drying, the concentration of the 
cryoprotectant showed critical impacts on the particle size, zeta potential, and structure, whereas 
freeze-drying time could highly affect the structure and stability due to its effects on the interactions 
between LOR and the excipients (stabilizer and cryoprotectant) (Alshweiat et al., 2018). Fig.6b 
illustrates the high severity of stabilizer type, stabilizer concentration, drug content, sonication time, 
sonication temperature, and solvent: antisolvent ratio as CPPs. 
6.2 Selection of process parameters for the development of LNS 
The QbD suggested the influential effects of CPP on the particle size and its consequences. Therefore, 
process parameters should be cautiously adjusted to support nanoscale production. In the case of 
ultrasonic-assisted precipitation, all precipitation and sonication parameters must be defined and 
selected according to the particle size reduction. For process optimization, the drug amount, and the 
stabilizer's type and concentration were fixed at 100 mg and 0.2% w/v of F68, respectively. 
Additionally, various solvent: antisolvent ratios, sonication temperatures, sonication times, and 
sonication powers were applied at fixed freeze-drying conditions. The optimized CPPs were selected 
in the light of MPS and PDI (Fig.7). Details and results of these experiments are thoroughly discussed 
in the work of Alshweiat et al. (Alshweiat et al., 2018). 
 
Figure 7: Critical process parameters for the preparation of LNSs and dry nanoparticles (DLN) 
(Alshweiat et al., 2018) 
In summary, LNSs suitable for further processing were prepared using the following process 
parameters; sonication time of 30 min, time, sonication power of 50% amplitude, sonication 
temperature of 4 ºC, and solvent:antisolvent ratio of 1:40.  
6.3 Effects of material parameters on particle size and stability of LNS  
Table 8 shows the MPS, PDI, and ZP for pure LOR and the prepared LNSs. The mean particle size 
for unprocessed LOR was approximately 4.6 μm. Moreover, LOR showed aggregations of a size larger 
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than 120 µm in the aqueous media. Using HPMC or PVP-K25 alone as a single stabilizer was 
insufficient to stabilize LOR nanoparticles. Adding either of these hydrophilic polymers alone yielded 
high MPS (4900 and 4212 nm, respectively) with a large particle size distribution as reflected by the 
PDI values (0.98 and 0.767, respectively) (Alshweiat et al., 2018). This failure to produce stable 
nanoparticles can be attributed to the weak adsorption of these polymers onto LOR’s surface, as well 
as to the poor dipole-dipole interaction between LOR and the polymers because of a low polar surface 
area of LOR (Bartzatt, 2017). SLS was also found to be inappropriate to stabilize the nanosuspensions 
due to insufficient and incomplete adsorption of SLS into the surfaces of LOR (Obeidat and Sallam, 
2014). SLS-containing LNSs were characterized by a MPS of 1496.3 nm and a PDI of 0.414. In 
contrast, Tween 80 and F68 were suitable to produce LNSs when they were used on their own. 
Combining SLS with F68 or PVP-K25 augmented the latter one’s favourable effects on 
nanosuspension stabilization, while the combination of Tween 80 or F68 with PVP-K25 did not induce 
any significant changes compared to Tween 80 or F68 alone.  
Different concentrations of F68 as a single stabilizer yielded different MPSs with an increasing 
diameter as concentration increased, due to a higher viscosity of the solutions, which hinders solvent 
diffusion and affects the transmission of ultrasonic waves.  
Drug concentration had a significant effect on particle size reduction. Using a fixed 1:1 ratio of 0.2% 
w/v of F68 and PVP-K25 as stabilizers, the smallest MPS was obtained with 100 mg of LOR. This can 
be explained by supersaturation, in which higher drug concentration led to a higher rate of nucleation, 
resulting in a large number of nuclei and thus a smaller particle size (Lonare and Patel, 2013). 
In another related study, QbD suggested process parameters were applied into different material that 
is not commonly used as a nanosuspensions stabilizers i.e Soluplus®. The concept of the QbD and the 
previously determined RA were followed to link the CPPs with the CQAs. 
Polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol (Soluplus®) is a graft copolymer with 
amphiphilic properties. This polymer could act as a stabilizer and also as a solubilizing agent in the 
formulations of poorly water-soluble drugs. The use of Soluplus® as a stabilizer for nanosuspensions 
has been reported in a few studies with improved solubility and bioavailability (Homayouni et al., 
2014; Nagy et al., 2012).  
LNSs were prepared with 0.2, 0.4, and 0.6%, w/v of Soluplus® (LNS16, LNS17, and LNS18, 
respectively). The effects of changing the stabilizers type on the previously studied CQAs of MPS, 
PDI, ZP, were evaluated. Soluplus® produced LNS with particle size smaller than the commonly used 
stabilizers (Alshweiat et al., 2019b). Soluplus® interacted with the nonpolar surface area of LOR and 
covered the newly formed surfaces, providing a steric hindrance to prevent recrystallization from the 
solution and aggregation of the primary particles. Accordingly, nanoparticles were generated with zeta 
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potential around -20 mV. Unlike F68, the particle size decreased with increased Soluplus® 
concentration. Higher concentrations of Soluplus® could stabilize the NS more effectively due to weak 
Ostwald ripening as the drug will diffuse slowly from the formed micelles (Yang et al., 2014). 
 
In conclusion, the selection of the material was based on the ability to produce LOR nanosuspensions 
of the smallest particle size. Thus, nanosuspensions with 0.6% Soluplus®, and 0.2% w/v F68 either as 
Table 8: Mean particle size (MPS), polydispersity index (PDI), and zeta potential (ZP) for LOR 
and LNSs (Alshweiat et al., 2019b, 2018) (Mean ± SD). 
ZP (mV) PDI MPS (nm) Stabilizer 
concentration 
(%w/v) 
Stabilizer type LOR (mg) Sample 
-7.7±5.28 0.71±0.18 4607.5±41.70 - - 100 LOR 
-13.4±4.02 0.98±0.03 4900.0±71.98 0.2 PVP-K25 100 LNS1 
-11.9±4.51 0.77±0.18 4212.0±14.14 0.2 HPMC 100 LNS2 
-54±7.75 0.42±0.11 1496.3±17.45 0.2 SLS 100 LNS3 
-23±6.51 0.22±0.03 414.9±9.02 0.2 Tween 80 100 LNS4 
-6.5±3.98 0.13±0.03 246.5±1.83 0.2 F68 100 LNS5 
-6.3±4.45 0.10±0.01 288.3±37.33 0.4 F68 100 LNS6 
-12.1±5.91 0.20±0.01 325.4±28.20 0.6 F68 100 LNS7 
-58.7±8.54 0.23±0.03 589.3±12.66 0.2+0.2 PVP-K25+SLS 100 LNS8 
-67.2±8.14 0.20±0.03 557.4±31.47 0.2+0.2 F68+SLS 100 LNS9 
-27.8±5.08 0.16±0.11 306.7±14.97 0.2+0.2 F68+PVP-K25 50 LNS10 
-4.81±4.11 0.11±0.02 276.5±2.69 0.2+0.2 F68+PVP-K25 75 LNS11 
-
11.14±4.89 
0.12±0.01 253.4±1.27 0.2+0.2 F68+PVP-K25 100 LNS12 
-
18.10±3.85 
0.12±0.03 265.6±20.79 0.2+0.4 F68+PVP-K25 100 LNS13 
-23.6±5.07 0.17±0.01 307.25±7.28 0.2+0.6 F68+PVP-K25 100 LNS14 
-22.9±4.39 0.20±0.02 423.4±15.06 0.2+0.2 Tween80+PVP-
K25 
100 LNS15 
-21.5±5.59 0.25±0.0 220.4±5.30 0.2 Soluplus® 100 LNS16 
-19.7±4.85 0.12±0.02 178.7±6.50 0.4 Soluplus® 100 LNS17 
-16.5±6.59 0.16±0.03 168.3±6.5 0.6 Soluplus® 100 LNS18 
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a single stabilizer or as a mixture with PVP-K25 at 1:1 or 1:2 ratios (LNS5, LNS12, LNS13, and 
LNS18) were selected to be dried and further analyzed to evaluate the morphology, thermal, structure, 
solubility, and dissolution characteristics.  
6.4 Effects of freeze-drying on particle size and stability 
Aggregation of the selected LNSs did not occur for 1 week upon storage at 4°C, and nanoscale size 
was preserved (Table 9). However, MPS increased for all the selected samples compared to the MPS 
measured on the day of preparation. Therefore, this storage time was enough for the nanosuspension 
to be transferred into the freeze-dryer and converted into dried nanoparticles. 
Table 9: Mean particle size (MPS), polydispersity index (PDI), and zeta potential (ZP) for selected 
LNSs after 7 day of storage at 4°C (Alshweiat et al., 2019b, 2018) (Mean ± SD, n=3). 
Sample MPS (nm) PDI ZP (mV) 
LNS5 276.1±17.11 0.14±0.05 -7.8±3.36 
LNS12 283.4±14.32 0.14±0.02 -17.4±5.23 
LNS13 294.1±11.61 0.14±0.04 -20.6±7.46 
LNS18 178.5±6.7 0.18±0.09 -19.0±1.40 
 
Other prepared DLNs were easily redistributed to their original volume at nanosized range with 
accepted PDI (Table 10) and higher ZP than corresponding nanosuspensions, probably due to 
enhanced specific interaction between LOR and the polymeric stabilizers during drying and hence 
stability (Kim and Lee, 2010).  
Table 10: Mean particle size (MPS), polydispersity index (PDI), and zeta potential (ZP) for the 
selected DLNs after reconstitution in water (Alshweiat et al., 2019b, 2018) (Mean ± SD, n=3). 
Sample MPS (nm) PDI ZP (mV) 
DLN5 406.80±16.32 0.24±0.02 -25.80±5.87 
DLN12 353.55±31.75 0.20±0.04 -22.35±5.62 
DLN13 441.42±37.90 0.25±0.02 -20.70±4.82 
DLN18 220.21±6.23 0.21±0.02 -23.81±4.43 
 
6.5 Characterization of LOR dry nanoparticles 
6.5.1 Morphology of DLNs 
Raw LOR showed irregular shapes of crystals with a particle size larger than 5 μm with aggregation 
resulting in a broad range of size distribution. Drug particles in the PMs also showed the crystals of 
LOR. DLN5, DLN12, and DLN13 were characterized by short rod shape particles in the nanoscale, 
while Soluplus®-containing sample (DLN18) had spherical particles at the nanosized scale embedded 
within the carriers. The surfaces of DLNs were smooth due to the uniform drug dispersion at the 
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molecular level (Alshweiat et al., 2018) (Fig.8). The SEM images confirmed the high impact of the 
stabilizer type on the morphology of the nanoparticles as it was expected by the RA part of the QbD 
(Fig.5). 
 
Figure 8: SEM images of (a) raw LOR, (b) DLN5, (c) DLN12, (d) DLN13, and (e) DLN18 
(Alshweiat et al., 2019b, 2018). 
6.5.2 Differential scanning calorimetry of DLNs  
Fig.9 shows the DSC thermograms of the raw materials, PMs, and DLNs. Pure LOR exhibited a single 
sharp endothermic peak at 135.5ºC, corresponding to its melting point. F68 also showed a single peak 
for its melting point at 55 ºC. For Soluplus® and PVP-K25, peaks corresponding to the evaporation of 
water appeared in the temperature range of 50–80 ºC (Ruan et al., 2005). The absence of LOR peaks 
in PM1 and PM2 may be ascribed to the effect of F68 as it melted at 55 ºC and dissolved LOR during 
further heating (Ahuja et al., 2007). DLN5, DLN12, and DLN13 showed two broad peaks, one at 55–
60 °C and the other at 110 °C. These thermal events could be related to trehalose, to the interactions 
between the drug, the stabilizer, and trehalose during freeze-drying, to the phenomenon of the drug's 
dissolving in the stabilizer or the transformation into the amorphous state. Alshweiat et al. (Alshweiat 
et al., 2018) reported further evaluation of freeze-dried excipients that emphasized the interaction of 
trehalose with LOR or the stabilizer during the freeze-drying. On the other hand, DLN18 showed 
thermal events at 90 °C due to the glass transition temperature of amorphous trehalose, at 211°C due 
to the melting of trehalose, and a broad peak at 270 °C related to trehalose decomposition (Alshweait 
et al., 2019b; Chang et al., 2017; Dolenc et al., 2009). 
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Figure 9: DSC diffractograms of (a) raw LOR, (b) PM1 (1.25:1 weight ratio of LOR: F68), (c) PM2 
(1.25:1:1 weight ratio of LOR:F68:PVP-K25), (d) PM3 (1:2.4 weight ratio of LOR:Soluplus®), (e) 
DLN5, (f) DLN12, (g) DLN13, and (h) DLN18 (Alshweiat et al., 2019b, 2018). 
6.5.3 Structural analysis of DLNs 
The XRPD-diffractogram of LOR displayed intense crystalline 2θ peaks between 5° and 30°, 
indicating its crystalline nature. The PMs showed the characteristic crystalline diffraction peaks of 
LOR. These findings could support the previous assumption related to the absence of LOR peaks in 
the DSC thermograms of PM1 and PM2. The DLNs showed the halo and the diffused pattern typical 
of amorphous material (Fig.10). The degree of crystalline index confirmed the amorphous form of the 
LOR in these samples (37, 37, 18.1, and 27%for DLN5, DLN12, DLN13, and DLN18, respectively). 
These observations support that the crystalline structure vanishes as a result of the precipitation and 
drying processes (Colombo et al., 2017). Moreover, XRPD diffractograms revealed the conversion of 
trehalose dihydrate to an amorphous anhydrate form. 
 
Figure 10: XRPD diffractograms of (a) raw LOR, (b) PM1 (1.25:1 weight ratio of LOR: F68), (c) 
PM2 (1.25:1:1 weight ratio of LOR:F68:PVP-K25), (d) PM3 (1:2.4 weight ratio of LOR:Soluplus®), 
(e) DLN5, (f) DLN12, (g) DLN13, and (h) DLN18 (Alshweiat et al., 2019b, 2018). 
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6.5.4 Fourier transform infrared spectroscopy of DLNs 
The FT-IR spectra of the raw materials and DLNs are presented in Fig.11. Pure LOR’s FT-IR spectrum 
is described by bands at approximately 997 cm−1 and 1,227cm−1 for Aryl C-Cl stretching and-C-N 
stretching of aryl N, respectively. There are two characteristic bands at 1560 and 1703 cm−1, 
corresponding to C-O bonds of the amide or ester groups. Bands from 3000 to 2850 cm−1 were related 
to the C-H bond. 
PMs spectra showed the characteristic peaks of pure LOR, indicating negligible interactions between 
the API and the excipients. On the other hand, DLN5, DLN12, DLN13, and DLN18 showed significant 
differences at 3532, 2900-2982, 1700, and 997–1171 cm-1. These shifts could be ascribed to the 
interaction of LOR with the excipients during freeze-drying. 
 
Figure 11: FT-IR spectra of (a) raw LOR, (b) PM1 (1.25:1 weight ratio of LOR: F68), (c) PM2 
(1.25:1:1 weight ratio of LOR:F68:PVP-K25), (d) PM3 (1:2.4 weight ratio of LOR:Soluplus®), (e) 
DLN5, (f) DLN12, (g) DLN13, and (h) DLN18 (Alshweiat et al., 2019b, 2018). 
 
6.5.5 Effect of drying process on drug-excipients interactions 
Using of pre-dispersion directly to prepare the NFs is a simple step. However, the LOR characteristics 
and interactions with the excipients could be different from the Freeze-dried nanoparticles. Therefore, 
evaluating the interactions between LOR and the excipient during preparation can be achieved by 
comparing the samples dried by varying methods.  
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Vacuum drying for 24 h at 25 °C was applied for the LNS to produce a sample corresponding to DLN5. 
Both samples contained equal amounts of LOR and F68 and were prepared by the same conditions of 
the precipitation-assisted ultrasonication method. However, TRE was added to dry one sample by 
freeze-drying to get DLN5. The XRPD diffractogram and FT-IR spectrum were compared to the raw 
LOR and the PM1 ones (Fig.12). The vacuum dried LNS showed the same characteristic FT-IR bands 
of raw LOR and PM. On the other hand, DLN5 showed alterations, as has been discussed earlier. 
Furthermore, the XRPD test confirmed the crystalline state of LOR in the vacuum dried LNS5, while 
DLN5 showed an amorphous state.  
 
Figure 12: (a) FT-IR of (a) raw LOR, (b) PM1 (1.25:1, weight ratio of LOR:F68), (C) DLN5, and 
(d) vacuum dried LNS5, vs (b) XRPD of (a) raw LOR, (b) PM1 (1.25:1, weight ratio of LOR:F68), 
(C) DLN5, and (d) vacuum dried LNS5. 
The presence of interactions between the components of excipient mixtures during freeze-drying also 
has been confirmed by freeze-dried excipients. The DSC showed a change in the thermogram of TRE 
in freeze-dried samples containing PVP-K25, as FD-(PVP-K25/TRE) and FD-(F68/PVP-K25/TRE) 
revealed the absence of the endothermic peak characteristic of TRE at 210°C (Fig.13) (Cardona et al., 
1997; Imamura et al., 2008; Taylor, 1998).  
 
Figure 13: DSC thermograms of ultrasonicated, freeze-dried excipients; F68, PVPK25, TRE, 
F68/PVP-K25, F68/TRE, PVP-K25/TRE, and F68/PVP-K25/TRE (Alshweiat et al., 2018). 
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FT-IR subtracted curves were generated by subtracting the FT-IR spectra of the excipients, including 
TRE from the spectra of the corresponding DLN5, DLN12, DLN13, PM1, and PM2 (Fig.14). The 
peaks of LOR in the subtracted curves of PMs were identical to the peak of pure LOR. However, the 
subtracted curves of DLNs showed additional peaks at 3532 cm-1 related to N-H and at 3100 cm-1 
related to weak stretching OH bonds. Peak weakening and broadening were observed at 1703 and 1500 
cm-1. These investigations revealed the presence of intermolecular hydrogen bond and dipole-dipole 
interactions, although no chemical decompositions were detected (Alshweiat et al., 2018). 
 
Figure 14: FT-IR spectra produced by subtracting the FT-IR spectra of the excipients from the 
spectra of corresponding DLNs and PMs.(a) DLN5-Excipients, (b) DLN12-Excipients, (c) DLN13-
Excipients, (d) PM1-Excipients, (e) PM2-Excipients compared to (f) LOR (Alshweiat et al., 2018). 
 
6.5.6 Solubility and in vitro release from DLNs 
Compared to pure LOR, DLNs showed enhanced saturation solubility in water and PBS of pH 7.4. 
The water solubility of nanoparticles was increased by approximately 5.5, 8.6, and 15.4-fold for DLN5, 
DLN12, and DLN13, respectively. On the other hand, solubility in PBS of pH 7.4 was enhanced by 
9.3, 8.0, and 8.6-fold for DLN5, DLN12, and DLN13. This enhancement could be related to the 
reduction in particle size and the wettability of the polymers. When the particle size was reduced from 
the micron-range to the nano-range, the overall surface area of all particles increased sharply. 
Therefore, dissolution based on Noyes–Whitney equation (Noyes and Whitney, 1897). Water 
solubility was increased by increasing concentrations of PVP-K25. This increment may be attributed 
to the anti-plasticizing activity of PVP-K25, which could retard the formation of the crystal lattice.  
For Soluplus®-based nanosuspension, DLN18 showed a 59.39 ± 5.18 μg mL-1 solubility of LOR in 
PBS (pH 7.4), this means 121-fold enhanced solubility compared to LOR. The factors responsible for 
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such enhancement could be related to the reduction in particle size and the higher wettability due to 
the Soluplus® polymers. 
Fig.15 shows the dissolution profiles for LOR, PMs, and DLNs at PBS of pH 7.4. Poor dissolution of 
LOR results in only 6% of the drug dissolving in 120 min. PM1 and PM2 showed higher dissolving of 
the drug (20.3 and 17.7%, respectively) due to the increased wettability of the drug powder. DLNs 
showed higher drug release than pure LOR and PMs as 30 and 42% of the drug was detected to be 
released in the first 10 min, followed by no further significant dissolution because the sink conditions 
were not applied. Enhanced drug release can be attributed to particle size reduction, which produces a 
higher surface area for dissolution, and possibly to better wettability (Jinno et al., 2006). 
In a careful estimation, DLN5 showed the highest rate of dissolution, which may be related to F68 that 
forms micelles and increases dissolution. On the other hand, decreasing concentrations of PVP-K25 
were found to improve dissolution due to increased viscosity around the stagnant layer. Additionally, 
the amorphous form is characterized by better solubility compared to the crystalline form (Lindfors et 
al., 2007). 
Alternatively, about 57% of LOR h released from the s Soluplus®-based dry nanoparticles (DLN18) 
in the first 15 min and 80% within 2 h. This could be related to the high surface area of the 
nanoparticles, while the corresponding physical mixture (PM3) showed a release of 4.7 within 2 h.  
The differences in dissolution rates between different samples could be related to the stabilizer type 
and concentration.  
 
Figure 15: Dissolution behaviours of LOR, PM1, PM2, PM3, DLN5, DLN12, DLN13, and DLN18 
at PBS, pH 7.4 (Alshweiat et al., 2019b, 2018). 
6.5.7 In vitro dissolution kinetics  
The enhancement of the dissolution efficiency at different time points and RD60 can be noticed for 
the DLNs. At 30 min, the DE value of the drug is only 1.6%. PMs also showed low values in the range 
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of 2.1–13%, while DLNs showed values in the range of 27–47.0%. Similar increments were observed 
at 60 and 120 min, the maximum DE was shown by DLN18 at 120 min (67.30%). RD60 of DLNs 
showed an observed enhancement compared to PMs as well. On the other hand, the MDT values of 
the DLNs were lower than LOR. However, DLN5, DLN12, and DLN18 showed lower values than 
DLN18 (Table 11). These findings demonstrated the higher and faster dissolution of DLNs compared 
to the raw LOR (Alshweiat et al., 2019b, 2018). 
Table 11: %DE, MDT, and RD60 min for LOR and DLNs (Alshweiat et al., 
2019b, 2018). 
Sample %DE30 %DE60 %DE120 MDT RD60min 
LOR 1.6 1.5 2.0 34.3 - 
PM1 13.6 17.6 18.6 6.6 4.2 
PM2 8.9 11.8 14.4 16.9 2.9 
PM3 2.1 2.4 3.2 32.0 1.6 
DLN5 36.7 40.1 43.5 5.0 9.7 
DLN12 27.2 28.7 29.0 0.5 6.9 
DLN13 32.9 33.9 33.4 1.2 8.2 
DLN18 47.0 58.2 67.3 11.2 38.3 
 
6.6 Nanosuspenion-based nasal formulations 
The selection of potential stabilizers for the nanosuspension of the nasal delivery application was based 
on three preconditions: 1. to have a significant reduction of particle size, 2. it should have a weak effect 
on drug solubility since that drug solubility in the stabilizer solution plays a significant role in the 
formation of a stable nanosuspension (Verma et al., 2009), and 3. the stabilizer should be used in a low 
concentration. Therefore, F68 of 0.2%, w/v was selected to be the stabilizer for the pre-dispersion over 
Soluplus® of 0.6%, w/v concentration, as the solubility of LOR in the 0.6% Soluplus® was 63.39 ± 
27.38 µg mL-1 compared to 2.25 µg mL-1 in 0.2% F68. Besides, the ability of F68 to stabilize the LOR 
nanosuspension at this low concentration.  
Based on the previous experiments for the preparation and characterization of LNS, LNS5 was selected 
as a base to prepare the pre-dispersion for the nasal formulations. However, the drug content was 
increased, and suitable dilution of the nanosuspension with 0.2%, w/v F68 was applied to control the 
final concentration of LOR and HA in the final nasal formulations. Accordingly, material and process 
parameters were set as 200 mg mL-1 of LOR concentration of in the solvent phase, 0.2% w/v F68 as 
an antisolvent phase, 1:40 (mL:mL) of solvent:antisolvent. Moreover, the sonication process was set 
for sonication time of 30 min, sonication temperature of 4 ºC, and sonication power of 50% amplitude. 
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6.6.1 Characterization of the nanoparticles in the nasal formulations 
The LOR pre-dispersion exhibited a particle size of 311.55 ± 5.16 nm, polydispersity index of 0.16 ± 
0.02, and zeta potential of -22.05 ± 2.75 mV, thus homogenous and stable nanosuspension was 
produced by the antisolvent precipitation assisted ultrasonication method. LOR in the LNS showed 
saturation solubility of 8.5 ± 0.65 μg mL-1 in PBS at pH, 5.6. Though, pure LOR showed solubility of 
1.63 ± 0.38 μg mL-1. After three days of storage, the particles of LNS showed a MPS of 319.45 ± 4.90 
nm, PDI of 0.17 ± 0.02, and ZP of -18.50 ± 4.33, respectively. 
The SEM images (Fig.16a) revealed the changes in the surface morphology between LOR and LNS. 
LOR showed an irregular rod-like crystal shape with aggregation. Conversely, LNS showed a uniform 
distribution of nanocrystals within the matrix of F68.  
The DSC thermograms (Fig.16b) depict the reduction of LOR particle size and crystallinity in LNS; 
LOR showed a single sharp endothermic peak at 135 °C. The LNS showed a peak at 55 °C related to 
F68 and a reduced intensity and shifted peak toward a lower melting point of LOR. 
XRPD (Fig.16c) diffractogram of LNS and LOR were similar. Therefore, the reduction of the melting 
point and intensity of LOR in the sample could be related to the particle size rather than crystallinity 
reduction (Murdande et al., 2015). Moreover, The FT-IR spectra showed that LNS preserved the 
characteristic bands of LOR, thus confirmed the compatibility between LOR and F68 (Alshweiat et 
al., 2018). 
In summary, the morphological and structural analyses have demonstrated that LOR was produced in 
the nano-range as a homogenous nanosuspension while it preserved the crystalline state of the drug 
(Alshweiat et al., 2020). 
 
Figure 16: LOR and vacuum dried LNS characterization of (a) SEM images, (b) DSC thermograms, 
(c) XRPD diffractograms, and (d) FTIR spectra (Alshweiat et al., 2020). 
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6.6.2 Characterization of the nasal formulations 
The prepared NFs appeared as viscous formulations. The samples showed drug content higher than 
90%, particularly 98.98 ± 1.2, 97.66 ± 4.2, 95.15 ± 3.4, and 92.99 ± 2.8 for NF1, NF2, NF3, and NF4, 
respectively. The pH of the samples was in the range of 6.3–6.4, hence within the acceptable range for 
nasal administration (pH of the nasal mucosa is 4.5- 6.5) (England et al., 1999). LOR is unionized at 
these pH values. Therefore, dissolution enhancement is not ascribed to the salt form of LOR (Popovi 
et al., 2009). 
The addition HA had significant effects on the particle size and zeta potential of the LOR 
nanosuspensions in the NFs, as the MPS and ZP were increased by the addition of HA. The MPS of 
LOR in NF1, NF2, NF3, and NF4 was 327.2 ± 8.23, 437.27 ± 28.60, 341.6 ± 11.84, and 450.63 ± 
24.30 nm, respectively. Their respective PDI values were 0.25 ± 0.04, 0.31 ± 0.07, 0.25 ± 0.04, and 
0.26 ± 0.03, respectively (Alshweiat et al., 2020). This significant increase in particle size could be 
attributed to the coating of the particles by HA (Shen et al., 2015). Moreover, the presence of HA in 
the formulation increased the negativity charge. The zeta potential values were -55.1 ± 5.67, -50.3 ± 
6.68, -45.9 ± 6.36, and -52.2 ± 6.91 mV for NF1, NF2, NF3, and NF4, respectively (Sharma et al., 
2016; Shen et al., 2015). 
6.6.3 Rheological properties of NFs 
The NFs showed a shear thinning-flow (pseudoplastic) (Fig.17a). The rheological behaviours of the 
NFs were similar to the corresponding blank solutions that contained 1 mg mL-1 and 5 mg mL-1 of HA 
in 0.2% w/v F68 noted as blank1 and blank5, respectively. The apparent viscosity of the NFs was 
decreased by increasing the shear rate, which is typical for sodium hyaluronate solutions (Fig.17b) 
(Krause et al., 2001). However, the reduced particle size of LOR showed higher viscosity than the 
blank samples. Therefore, the nanosized LOR improved the viscosity of blank solutions. Comparable 
outcomes are reported by the work of Bartos et al. (Bartos et al., 2015). Apart from this, the viscosity 
of the formulations was related to the used HA polymer concentration. 1 mg mL-1 containing NFs (NF1 
and NF3) showed lower values than 5 mg mL-1 containing NFs (NF2 and NF4) (Alshweiat et al., 2020).  
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Figure 17: (a) The flow curves, and (b) the apparent viscosity of the NFs, blank1, and blank5 
samples at 37 ºC (Mean ± SD, n=3) (Alshweiat et al., 2020). 
The viscosity of the NFs was related to the used HA polymer concentration. 1 mg mL-1 containing NFs 
(NF1 and NF3) showed lower values than 5 mg mL-1 containing NFs (NF2 and NF4).  
6.6.4 Mucoadhesion of the nasal formulations 
Samples with and without mucin were prepared to evaluate the role of LOR nanosuspension in 
mucoadhesion. The bioadhesive viscosity component, synergism parameter, was calculated from the 
average viscosity values. The systems of NFs and 5% mucin (NF-M) showed shear-thinning 
behaviours. The viscosity of the NF-M systems was higher than the corresponding NF (Fig.18) due to 
the polymer or mucin entanglement, and interactions between the polymer and mucin via the hydrogen 
bonds (Thirawong et al., 2008). 
 
Figure 18: The observed viscosity of NFs and the combined NF with mucin (NF-M) at 37 ºC (Mean 
± SD, n=3) (Alshweiat et al., 2020). 
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The synergism parameters (ƞb) of the NFs were compared to the F68 solution, corresponding REF 
samples, and the corresponding blanks (Fig.19). The blanks showed mucoadhesive properties, 
depending on the concentration of the sodium hyaluronate. The values of the bioadhesive viscosity 
were 0.60 and 46.5 mPa*s for blank1 and blank5, respectively. The negative values ƞb of REF1 and 
REF3 could be related to the insufficient amount of HA to interact with the mucin. The addition of the 
LNS to the blanks increased the mucoadhesivity of the formulations. This effect could be related to 
the interactions between the mucin and the dispersed nanosized LOR particles (Alshweiat et al., 2020). 
The synergism effect was directly linked to the HA and nanosized drug amount. These outcomes could 
be related to a higher interaction of the HA with the mucin and the nanocrystals. Accordingly, NF4 
showed the highest synergism parameter. The ƞb was 2.8-fold compared to blank5. The nanosized 
LOR was in the size of polymeric molecules of HA and mucin chains, hence better interaction among 
the components and higher mucoadhesivity could be obtained (Horvát et al., 2009).  
 
Figure 19: Calculated synergism parameters of blanks, REF, and NF samples at a shear rate of 100 
s-1 and 37 ºC (Mean ± SD, n=3) (Alshweiat et al., 2020). 
NF4 that showed the highest mucoadhesive parameter. Therefore, it was selected for further studies. 
6.6.5 Effects of nanosizing on the dissolution, diffusion, and permeability 
LOR shows a poor water solubility. Thus, many studies suggested the use of 900 mL of dissolution 
media or/and the addition of surfactant or co-solvent in the dissolution media to attain sink conditions 
(Damian et al., 2016; Song and Shin, 2009; Vlaia et al., 2017). In this study, the sink conditions were 
not applied due to factors related to the limited volume of the nasal delivery, lack of surfactant on the 
nasal cavity to be simulated by the dissolution media and to evaluate the effect of the particle size 
reduction on dissolution and diffusion without any interventions from the surfactant. Moreover, the 
NF4 solubility in the ANF was 6.43 ± 1.68 μg mL-1. Thus, drug content was too high (0.14 mg ± 1.68) 
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to fulfil the sink conditions. NF4 formulation was compared to REF4. NF4 showed an enhanced drug 
release compared to the reference sample (Fig.20a). Approximately 77% of the drug was released from 
NF4 within the first 15 min compared to 10% from the reference sample (Alshweiat et al., 2020). 
These differences in dissolution rates could be related to the nanosizing effects, as small particles 
produced a higher surface area than the microparticles. Thus, dissolution according to the Noys-
Whitney equation. Moreover, the nanosizing of LOR showed a 5.2-fold saturation solubility compared 
to the raw drug (Agrawal and Patel, 2011).  
 
Figure 20: (a) Dissolution profile, and (b) In vitro permeability of NF4 and REF4 in ANF media at 
37 ºC (Mean ± SD, n=3) (Alshweiat et al., 2020). 
The diffusion indicates the permeation property. In this study, the membrane pore size was 100 nm, 
so LOR particles were unable to pass directly through the membrane. Consequently, the high surface 
area achieved by the nanosized particles was the main factor affecting the rate of passive diffusion.  
The diffusion from NF4 was faster than REF4 due to the higher dissolution of the drug (Fig.20b). LOR 
diffused immediately from NF4 while it was diffused after 10 min from the REF4. The flux (J) 
represents the amount of LOR permeated through a 1 cm2 of the membrane within 1h. NF4 that 
contained LOR nanoparticles showed a significantly increased J compared to REF4 (24.73 ± 3.2 and 
1.49 ± 1.03 µg cm-² h-1, respectively). Therefore, HA containing-formulations allowed the penetration 
of LOR through the synthetic membrane. However, the flux of the nanosized-based formulation was 
higher than the reference sample containing the raw LOR. The permeability coefficient (Kp) of NF4 
also showed a higher value than REF4. Kp values were 0.082 and 0.017 cm h-1, respectively. In 
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particular, 11.15 µg cm-² of the drug diffused in the first 15 min from the NF4 compared to 0.56 µg 
cm-² from the REF4. The higher diffusion could be connected to the higher surface area produced by 
the nanoparticles. The viscosity of the NF4 was at a low level that is suitable for nasal spray (Bartos 
et al., 2018). 
6.6.6 In vivo studies of the selected NF 
Nanosuspension based LOR was designed to improve the drug bioavailability by the intranasal route. 
Plasma levels after intranasal administration of the nanoparticle formulations were compared with 
those achieved with a reference sample that contained unprocessed suspended LOR (REF4). 
Moreover, nasal delivery was compared to the oral one. Fig.21a shows the mean LOR plasma 
concentration-time profiles after intranasal and oral delivery of NF4 and REF4. 
 
Figure 21: (a) Plasma concentration of LOR, and (b) AUC 0– ∞ (h nmol L
-1) of plasma after nasal 
and oral administration of NF4 and REF4 (*, P=0.02; **, P=0.003, ***, P=0.0003) (Mean ± SD, 
n=4) (Alshweiat et al., 2020). 
LOR belongs to class II of the BCS. Thus it shows good permeability. Cmax after the nasal 
administration is significantly higher than the oral administration (P ≤ 0.01). The Cmax was 6.39, 13.29, 
38.36, and 39.99 nM for REF4-oral, NF4-oral, REF4-nasal, and NF4-nasal, respectively (Table 12). 
The higher nasal concentrations could be related to higher absorption through the high vascularized 
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mucosa and bypassing the first-pass metabolism. Moreover, HA could act as a permeation enhancer 
for LOR through the nasal mucosa (Illum et al., 1994). Apart from this, the plasma concentration of 
REF4-oral, REF4-nasal, and NF4-oral decreased after 12 h. However, NF4-nasal plasma concentration 
was 3.85 nmol L-1 and still detected to 24 h resulting in lower ke (Alshweiat et al., 2020). 
Table 12: Pharmacokinetics parameters of LOR concentration in plasma after administration 
of NF4 and REF4 using oral and intranasal administration (Mean ± SD, n = 4) (Alshweiat et 
al., 2020).  
 
 Oral Intranasal 
REF4  NF4 REF4  NF4 
AUC0-∞ [h nmol L-1]     17.81±1.96      36.59±9.79       110.35±10.41     202.71±43.31 
Cmax [nM] 6.39±2.21     13.29±5.72      38.36±9.78       39.99±14.18 
ke [h-1] 0.24±0.03 0.24±0.03 0.24±0.09 0.12±0.01 
 
The mucoadhesive properties for the nanosuspension in NF4 were visible as mucoadhesion would 
improve the drug absorption and could prolong the intimate contact time of the particle on the nasal 
mucosa by adhering to the surface of the mucus layer. Therefore, NF4 showed extended and elevated 
plasma concentration of LOR than REF4, considering the exclusion of the mucoadhesive agent 
consequences as the samples contained the same concentrations of HA (Morimoto et al., 1991). 
Fig.20b shows the AUC 0- ꝏvalues (Table 12) for LOR after oral and nasal administration. The relative 
bioavailability of the intranasal delivered NF4 was 1.84-fold compared to the REF4 and 5.54-fold 
compared to the oral delivered sample i.e. NF4-oral. These findings provide evidence that nasal 
administration enhanced the bioavailability of LOR. Moreover, the nanoparticles are practical to 
improve the delivery of LOR through the nasal route (Alshweiat et al., 2020). 
6.6.7 Stability of the selected NF 
The selected NF4 sample showed no significant change in terms of physical appearance and viscosity. 
Furthermore, no particle precipitation occurred over 6 weeks for the samples kept at 4 ºC. Though, the 
samples at 25 ºC showed precipitation and phase separation. Thus, the storage of formulations would 
be more appropriate at refrigerated conditions to ensure the stability of the products. The drug content 
of NF4 samples after the storage period at 4 °C was 89.48 ± 3.60% (Alshweiat et al., 2020). The mean 
particle size of LOR nanosuspension in NF4 was 425.50 ± 14.50 nm. Moreover, the NF4 showed a 
PDI of 0.37 ± 0.05 and zeta potential of - 42.60 ± 7.98 mV. The stability of the formulation could be 
related to the high zeta potential and the viscosity of the formulation that kept the LOR nanoparticles 
separated and homogeneously distributed through the matrix (Müller and Jacobs, 2002). Moreover, 
the reduction of particle size after the storage period compared to the fresh samples could be related to 
the drug-stabilizer interactions (Md et al., 2018). 
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7. CONCLUSIONS 
In this study, a novel combined-method of preparation was used to develop loratadine nasal 
formulation. The combination of nanosuspension and simple addition of a mucoadhesive agent 
presented a promising platform for the nasal delivery of loratadine.  
 Quality by design (QbD) was implemented to define the QTPP of the final nasal formulation as 
well as the CQAs, CMPs, and CPPs for the preparation of the LOR nanosuspensions. The RA was 
used to evaluate the influential effects of the CMPs and CPPs according to the required CQAs. 
 Process and material parameters were demonstrated to have a pronounced effect on controlling the 
properties of the final nanoparticles. The optimized process parameters were set to 30 min time, 4 
°C temperature, and 50% power. At fixed amount of drug (100 mg), the nanosuspension showed a 
MPS range of 256, 253, and 265 nm when 0.2% F68, 0.2% of F68 and 0.2% of PVP-K25, and 
0.2% of F68 and 0.4% of PVP-K25, respectively. The PDI was less than 0.25 using the previously 
mentioned stabilizers. The increase of the amount of the drug to 200 mg produced nanoparticles 
having a mean particle size of 312, polydispersity of 0.16, and zeta potential of -22.05 mV, thus 
homogenous and stable nanosuspension. On the other hand, using Soluplus® as a stabilizer showed 
great potential for the preparation of LOR nanosuspensions. 
 Nanosuspension has been used as a pre-dispersion for the preparation of nasal formulation as a 
simple and straightforward strategy. The reduction of particle size presented enhanced properties 
of the nasal formulation rheology. Moreover, using a mucoadhesive agent is crucial to extend the 
contact time between the formulation and nasal mucosa. NF4 formulation that contained 2.5 mg 
mL-1 of loratadine and 5 mg mL-1 sodium hyaluronate showed enhanced rheological behaviours, 
where nanosizing had the main effect in the mucoadhesive properties. NF4 showed enhanced 
dissolution in an artificial nasal fluid. Besides, higher diffusion and permeability coefficient 
compared to the unprocessed loratadine. 
 The in vivo studies showed the superiority of nasal delivery over the oral administration. Moreover, 
the nanoparticles showed higher AUC0–∞ compared to the unprocessed LOR. 
 Nanosupension-based nasal formulation (NF4) showed no significant change in terms of physical 
appearance and viscosity. Furthermore, no particle precipitation occurred over 6 weeks for the 
samples kept at 4 ºC. The NF4 showed a mean particle sze of 425.5 ± 14.5, a polydispersity of 0.37 
± 0.05, and zeta potential of -42.6 ± 7.98. The stability of the formulation could be related to the 
high zeta potential and the viscosity of the formulation that kept the LOR nanoparticles separated 
and homogeneously distributed through the matrix.  
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8. NOVELTY AND PRACTICAL ASPECTS 
The delivery of poorly water-soluble drugs requires the need of high bioavailability to achieve 
consistent therapeutic outcomes. In industry, the selection of the preparation and the delivery 
technology is not only driven by therapeutic targets, but also by technical aspects, such as simplicity, 
scalability, the time required for production, and production costs. 
 The novelty and power of the presented work based on its ability to control and compromise 
different aspects from analyzing the literature to select the route of administration to produce LOR 
in a new dosage form that has not been studied and developed before. 
 Applying QbD rationalized the selection of the methodologies and the route of the administration, 
significantly improved the targetability of getting optimized formulations in the voice of 
predefined quality and safety. 
 Optimization of critical parameters to produce LOR's nanosuspension is considered a significant 
step toward extending the application of precipitation-assisted ultrasonication methods to 
formulate different APIs as nanosuspension-based dosage forms. By these findings, this method 
can compete with the top-down one in the development of potential products for the market. 
 A novel formulation of LOR has been developed based on the nanosuspension of the drug. The 
prepared nasal formulation showed an improved bioavailability of LOR. Therefore, this 
formulation could offer new possibilities for the delivery of LOR as a new dosage form.  
 A combination of the nanosuspension and the simple addition of a mucoadhesive agent could 
suggest a promising platform for the nasal delivery of various poorly water-soluble drugs. 
 Developing nasal formulation with an improved bioavailability compared to oral delivery could 
boost the chances for the nasal formulations to enter the market. 
 The applicability of nanosuspensions as a nasal delivery system to the systemic circulation is a 
new approach in pharmaceutical technology. 
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